prescription attached:-

đŠē LIPU MED â FULL CLINICAL PRESCRIPTION REVIEW & DIAGNOSTIC ASSESSMENT
āĻŦāĻžāĻāϞāĻž āϰā§āĻāύāĻŋāϰā§āĻŖāϝāĻŧ: āϰāĻžāϤ⧠āĻŦāĻžāϰāĻŦāĻžāϰ āĻĒā§āϰāϏā§āϰāĻžāĻŦ āĻšāĻāϝāĻŧāĻžâāϏāĻŽā§āĻāĻžāĻŦā§āϝ āĻŽā§āϤā§āϰāĻĨāϞāĻŋāϰ āĻāĻžāϰā§āϝāĻāĻžāϰāĻŋāϤāĻžāĻāύāĻŋāϤ āϏāĻŽāϏā§āϝāĻž āĻ āĻĨāĻŦāĻž āĻŽā§āϤā§āϰāύāĻžāϞā§āϰ āϏāĻāĻā§āϰāĻŽāĻŖ; āĻāĻāϝāĻŧ āĻāĻžāĻāϧ āĻ āĻā§āĻŽāϰ⧠āĻŦā§āϝāĻĨāĻžāĨ¤ āĻĒā§āϰāĻĻāĻžāĻšāĻāύāĻŋāϤ āĻŦāĻžāϤāϰā§āĻā§āϰ āϏāĻŽā§āĻāĻžāĻŦāύāĻžāĻ āĻĒāϰā§āĻā§āώāĻž āĻāϰ⧠āĻĻā§āĻāϤ⧠āĻšāĻŦā§āĨ¤
Clinical status: Provisional Working Assessment â āϰā§āĻā§āϰ āĻāĻĒāϏāϰā§āĻ āĻ āĻĒā§āϰā§āϏāĻā§āϰāĻŋāĻĒāĻļāύāĻāĻŋāϤā§āϤāĻŋāĻ āĻĒā§āϰāĻžāĻĨāĻŽāĻŋāĻ āĻŽā§āϞā§āϝāĻžāϝāĻŧāύ; āύāĻŋāĻļā§āĻāĻŋāϤ āϰā§āĻāύāĻŋāϰā§āĻŖāϝāĻŧ āύāϝāĻŧāĨ¤
Patient: Mrs. Minoty Roy
Age: 85 years
Prescription Date: Saturday, 10 October 2026
Prescribing Physician: Dr. Torequl Islam Tonmoy
Review Date: Friday, 16 October 2026
Department: Urology â with Rheumatology and Geriatric Medicine considerations.
Website verification: Raiyyan Tahsan Medical Blog Archive āĻāĻŦāĻ Urology Case Archive āϝāĻžāĻāĻžāĻ āĻāϰāĻž āĻšāϝāĻŧā§āĻā§āĨ¤ āϏāϰā§āĻŦāĻļā§āώ āĻĻā§āĻļā§āϝāĻŽāĻžāύ Total Case 1376, Urology Department Code 23 āĻāĻŦāĻ Urology Case No 24āĨ¤ āϏā§āĻ āĻ āύā§āϝāĻžāϝāĻŧā§ āĻāĻ āύāϤā§āύ, āĻāĻāύ⧠āĻ āĻĒā§āϰāĻāĻžāĻļāĻŋāϤ āύāĻŋāĻŦāύā§āϧā§āϰ āĻĒā§āϰāϏā§āϤāĻžāĻŦāĻŋāϤ āύāĻŽā§āĻŦāϰ TC(1377).(23), Case No (25)āĨ¤ āĻĒā§āϰāĻāĻžāĻļā§āϰ āĻāĻā§ āĻĒā§āύāϰāĻžāϝāĻŧ āϝāĻžāĻāĻžāĻ āĻāϰāϤ⧠āĻšāĻŦā§āĨ¤
Overall diagnostic confidence: 0.56/1.00 â Moderateâlow. āĻāĻžāϰāĻŖ āϰā§āĻā§āϰ āĻŦāĻŋāϏā§āϤāĻžāϰāĻŋāϤ āĻāϤāĻŋāĻšāĻžāϏ, āĻļāĻžāϰā§āϰāĻŋāĻ āĻĒāϰā§āĻā§āώāĻž āĻāĻŦāĻ āύāĻŋāϰā§āĻĻā§āĻļāĻŋāϤ āĻĒāϰā§āĻā§āώāĻžāĻā§āϞā§āϰ āĻĢāϞāĻžāĻĢāϞ āĻĒāĻžāĻāϝāĻŧāĻž āϝāĻžāϝāĻŧāύāĻŋāĨ¤
Important Clinical Safety Alert: ā§Žā§Ģ āĻŦāĻāϰ āĻŦāϝāĻŧāϏ⧠āĻāĻ āϰā§āĻā§āϰ āĻĒā§āϰā§āϏāĻā§āϰāĻŋāĻĒāĻļāύ⧠Tofacitinib, Sulindac, Nitrofurantoin, Mirogabalin āĻāĻŦāĻ āĻāϰāĻ āĻāϝāĻŧā§āĻāĻāĻŋ āĻāώā§āϧ āϰāϝāĻŧā§āĻā§āĨ¤ āĻŦāĻŋāĻļā§āώ āĻāϰ⧠Brofex TS-āĻāϰ āϞāĻŋāĻāĻŋāϤ āĻĄā§āĻ MedEx-āĻāϰ āϏāϰā§āĻŦā§āĻā§āĻ āĻĻā§āύāĻŋāĻ āĻĄā§āĻā§āϰ āĻŦā§āĻļāĻŋ āĻšāϤ⧠āĻĒāĻžāϰā§āĨ¤ āĻāώā§āϧāĻā§āϞā§āϰ āύāĻŋāϰāĻžāĻĒāϤā§āϤāĻž, āĻāĻŋāĻĄāύāĻŋāϰ āĻāĻžāϰā§āϝāĻāĻžāϰāĻŋāϤāĻž āĻāĻŦāĻ āϏāĻŽā§āĻāĻžāĻŦā§āϝ āĻĒāĻžāϰāϏā§āĻĒāϰāĻŋāĻ āĻĒā§āϰāϤāĻŋāĻā§āϰāĻŋāϝāĻŧāĻž āĻĻā§āϰā§āϤ prescribing doctor āĻŦāĻž clinical pharmacist āĻĻāĻŋāϝāĻŧā§ āĻĒā§āύāĻāϝāĻžāĻāĻžāĻ āĻāϰāĻž āĻĒā§āϰāϝāĻŧā§āĻāύāĨ¤ āĻāĻ āĻĒāϰā§āϝāĻžāϞā§āĻāύāĻž āĻā§āύ⧠āĻāώā§āϧ āύāĻŋāĻā§ āĻĨā§āĻā§ āĻļā§āϰ⧠āĻŦāĻž āĻŦāύā§āϧ āĻāϰāĻžāϰ āύāĻŋāϰā§āĻĻā§āĻļ āύāϝāĻŧāĨ¤
1. Patient Information â āϰā§āĻā§āϰ āĻĒāϰāĻŋāĻāĻŋāϤāĻŋ
| Clinical Parameter | Prescription Findings | āĻŦāĻžāĻāϞāĻž āĻŦā§āϝāĻžāĻā§āϝāĻž | Confidence |
|---|---|---|---|
| Patient Name | Mrs. Minoty Roy | āĻŽāĻŋāϏā§āϏ āĻŽāĻŋāύāϤāĻŋ āϰāĻžāϝāĻŧ | 0.98 |
| Age | 85 Years | āĻŦāϝāĻŧāϏ ā§Žā§Ģ āĻŦāĻāϰ | 0.99 |
| Sex | Female | āύāĻžāϰ⧠| 0.99 |
| Prescription Date | 10-10-2026 | ā§§ā§Ļ āĻ āĻā§āĻā§āĻŦāϰ ⧍ā§Ļ⧍ā§Ŧ | 0.99 |
| Blood Pressure | 110/70 mmHg | āϰāĻā§āϤāĻāĻžāĻĒ ā§§ā§§ā§Ļ/ā§ā§Ļ | 0.99 |
| Pulse | 96 bpm | āĻĒā§āϰāϤāĻŋ āĻŽāĻŋāύāĻŋāĻā§ āĻšā§āĻĻāϏā§āĻĒāύā§āĻĻāύ ⧝ā§Ŧ | 0.98 |
| SpOâ | 99% | āϰāĻā§āϤ⧠āĻ āĻā§āϏāĻŋāĻā§āύ āϏā§āϝāĻžāĻā§āϰā§āĻļāύ ⧝⧝% | 0.99 |
| Temperature | Not documented | āĻļāϰā§āϰā§āϰ āϤāĻžāĻĒāĻŽāĻžāϤā§āϰāĻž āϞā§āĻāĻž āύā§āĻ | 0.99 |
| Weight | Not documented | āĻāĻāύ āϞā§āĻāĻž āύā§āĻ | 0.99 |
| Drug Allergy | Not documented | āĻāώā§āϧ⧠āĻ ā§āϝāĻžāϞāĻžāϰā§āĻāĻŋāϰ āĻāϤāĻŋāĻšāĻžāϏ āύā§āĻâāĻāĻŽāύ āϤāĻĨā§āϝ āĻĻā§āĻāϝāĻŧāĻž āĻšāϝāĻŧāύāĻŋ | 0.99 |
Clinical interpretation: āϰāĻā§āϤāĻāĻžāĻĒ āĻ āĻ āĻā§āϏāĻŋāĻā§āύ āϏā§āϝāĻžāĻā§āϰā§āĻļāύ āϤāĻžā§āĻā§āώāĻŖāĻŋāĻāĻāĻžāĻŦā§ āĻāĻļāĻā§āĻāĻžāĻāύāĻ āύāϝāĻŧāĨ¤ Pulse 96 bpm āϏā§āĻŦāĻžāĻāĻžāĻŦāĻŋāĻ āϏā§āĻŽāĻžāϰ āĻāϰā§āϧā§āĻŦāĻĻāĻŋāĻā§, āĻāĻŋāύā§āϤ⧠āĻļā§āϧ⧠āĻāĻ āĻŽāĻžāύ āĻĻāĻŋāϝāĻŧā§ Tachycardia āύāĻŋāϰā§āĻŖāϝāĻŧ āĻāϰāĻž āϝāĻžāϝāĻŧ āύāĻžāĨ¤ āĻŦāϝāĻŧāϏ, āϏāĻāĻā§āϰāĻŽāĻŖā§āϰ āϏāĻŽā§āĻāĻžāĻŦāύāĻž, āĻŦā§āϝāĻĨāĻž āĻāĻŦāĻ āĻāώā§āϧā§āϰ āĻĒāĻžāϰā§āĻļā§āĻŦāĻĒā§āϰāϤāĻŋāĻā§āϰāĻŋāϝāĻŧāĻž āĻŦāĻŋāĻŦā§āĻāύāĻž āĻāϰāĻž āĻĻāϰāĻāĻžāϰāĨ¤
Confidence: 0.95
2. Chief Complaints (C/C) â āϰā§āĻā§āϰ āĻĒā§āϰāϧāĻžāύ āĻ āĻāĻŋāϝā§āĻ
āĻĒā§āϰā§āϏāĻā§āϰāĻŋāĻĒāĻļāύā§āϰ āĻŦāĻžāĻŽ āĻĒāĻžāĻļā§ C/C āĻšāĻŋāϏā§āĻŦā§ āĻĒāĻžāĻāĻāĻāĻŋ āĻ āĻāĻŋāϝā§āĻ āϞā§āĻāĻž āĻāĻā§āĨ¤
| No. | Doctor’s Written C/C | āĻŦāĻžāĻāϞāĻž āĻ āϰā§āĻĨ | Clinical Significance |
|---|---|---|---|
| 1 | Nocturia | āϰāĻžāϤ⧠āĻā§āĻŽ āĻĨā§āĻā§ āĻāĻ ā§ āĻĒā§āϰāϏā§āϰāĻžāĻŦ āĻāϰāϤ⧠āĻšāϝāĻŧ | OAB, UTI, nocturnal polyuria, diabetes āĻŦāĻž āĻ āύā§āϝāĻžāύā§āϝ āĻāĻžāϰāĻŖā§ āĻšāϤ⧠āĻĒāĻžāϰ⧠|
| 2 | LBP | Low Back Pain â āĻā§āĻŽāϰā§āϰ āύāĻŋāĻā§āϰ āĻ āĻāĻļā§ āĻŦā§āϝāĻĨāĻž | Musculoskeletal, degenerative āĻŦāĻž neurological āĻāĻžāϰāĻŖ |
| 3 | Pain â Both Shoulders | āĻāĻāϝāĻŧ āĻāĻžāĻāϧ⧠āĻŦā§āϝāĻĨāĻž | OA, inflammatory arthritis, PMR āĻ āĻĨāĻŦāĻž rotator cuff disease |
| 4 | Insomnia | āĻ āύāĻŋāĻĻā§āϰāĻž | āĻŦā§āϝāĻĨāĻž, Nocturia āĻ āĻĨāĻŦāĻž āĻ āύā§āϝ āϏāĻŽāϏā§āϝāĻžāϰ āĻāĻžāϰāĻŖā§ āĻā§āĻŽā§āϰ āĻŦā§āϝāĻžāĻāĻžāϤ |
| 5 | Common Cold | āϏāĻžāϧāĻžāϰāĻŖ āϏāϰā§āĻĻāĻŋ | āϏāĻŽā§āĻāĻžāĻŦā§āϝ Viral Upper Respiratory Tract Infection |
Confidence: 0.99 â Prescription transcription.
Clinical significance
Nocturia: āĻāĻāĻŋ āĻāĻāĻāĻŋ āĻāĻĒāϏāϰā§āĻ, āϰā§āĻā§āϰ āύāĻžāĻŽ āύāϝāĻŧāĨ¤ āϰāĻžāϤ⧠āĻāϤāĻŦāĻžāϰ āĻĒā§āϰāϏā§āϰāĻžāĻŦ āĻšāϝāĻŧ, āĻĒā§āϰāϤāĻŋāĻŦāĻžāϰ āĻāϤāĻāĻž āĻĒā§āϰāϏā§āϰāĻžāĻŦ āĻšāϝāĻŧ āĻāĻŦāĻ āĻĒā§āϰāϏā§āϰāĻžāĻŦā§āϰ āĻŦā§āĻ āύāĻŋāϝāĻŧāύā§āϤā§āϰāĻŖ āĻāϰāĻž āϝāĻžāϝāĻŧ āĻāĻŋ āύāĻžâāĻāϏāĻŦ āϤāĻĨā§āϝ āĻāĻžāĻĄāĻŧāĻž Overactive Bladder āύāĻŋāĻļā§āĻāĻŋāϤ āĻāϰāĻž āϝāĻžāϝāĻŧ āύāĻžāĨ¤
Bilateral shoulder pain: āĻāĻ āĻŦāϝāĻŧāϏ⧠Osteoarthritis, Rotator Cuff Disease, Rheumatoid Arthritis āĻāĻŦāĻ Polymyalgia Rheumatica āĻŦāĻŋāĻŦā§āĻāύāĻž āĻāϰāϤ⧠āĻšāĻŦā§āĨ¤ āĻļā§āϧ⧠āĻĻā§āĻ āĻāĻžāĻāϧ⧠āĻŦā§āϝāĻĨāĻž āĻĨāĻžāĻāϞā§āĻ Rheumatoid Arthritis āĻšāϝāĻŧ āύāĻžāĨ¤
Insomnia: Nocturia āĻāĻŦāĻ āĻĻā§āϰā§āĻāϏā§āĻĨāĻžāϝāĻŧā§ āĻŦā§āϝāĻĨāĻž āĻā§āĻŽā§āϰ āĻŦā§āϝāĻžāĻāĻžāϤ āĻāĻāĻžāϤ⧠āĻĒāĻžāϰā§āĨ¤ āϤāĻŦā§ āĻ āύāĻŋāĻĻā§āϰāĻžāϰ āύāĻŋāϰā§āĻĻāĻŋāώā§āĻ āĻāĻžāϰāĻŖ āĻāĻ āĻĒā§āϰā§āϏāĻā§āϰāĻŋāĻĒāĻļāύ⧠āĻĒā§āϰāϤāĻŋāώā§āĻ āĻŋāϤ āĻšāϝāĻŧāύāĻŋāĨ¤
Confidence: 0.91 â General clinical interpretation; patient-specific etiology remains unconfirmed.
3. Clinical History Review â O/H, D/H, M/H, O/S/E
āĻāĻāĻžāύ⧠Not documented āĻāĻŦāĻ Negative history āĻāĻ āĻŦāĻŋāώāϝāĻŧ āύāϝāĻŧāĨ¤ āĻā§āύ⧠āĻāϤāĻŋāĻšāĻžāϏ āϞā§āĻāĻž āύāĻž āĻĨāĻžāĻāϞ⧠āϏā§āĻāĻŋāĻā§ āϰā§āĻā§āϰ āĻāϤāĻŋāĻšāĻžāϏ āϏā§āĻŦāĻžāĻāĻžāĻŦāĻŋāĻ āĻŦāϞ⧠āϧāϰāĻž āϝāĻžāĻŦā§ āύāĻžāĨ¤
| History/Examination | Doctor’s Documentation | Assessment |
|---|---|---|
| O/H â Obstetric History | Not documented | āϏāύā§āϤāĻžāύāϧāĻžāϰāĻŖ āĻ āĻĒā§āϰāϏāĻŦā§āϰ āĻāϤāĻŋāĻšāĻžāϏ āĻ āĻāĻžāύāĻž |
| D/H â Drug History | Not documented separately | āĻĒā§āϰā§āĻŦ āĻĨā§āĻā§ āĻā§ āĻāώā§āϧ āĻā§āϤā§āύ, āĻāĻžāύāĻž āύā§āĻ |
| M/H â Medical History | Not documented | DM, HTN, CKD, RA, CAD-āĻāϰ āĻāϤāĻŋāĻšāĻžāϏ āĻ āĻāĻžāύāĻž |
| O/S/E â Systemic Examination | Not documented | āĻĒā§āϰā§āĻŖ Systemic Examination āύā§āĻ |
| O/G/E â General Examination | BP, Pulse, SpOâ documented | āϏā§āĻŽāĻŋāϤ Vital Signs āĻĒāĻžāĻāϝāĻŧāĻž āĻā§āĻā§ |
| Surgical History | Not documented | āĻ āĻĒāĻžāϰā§āĻļāύā§āϰ āĻāϤāĻŋāĻšāĻžāϏ āĻ āĻāĻžāύāĻž |
| Family History | Not documented | āĻĒāĻžāϰāĻŋāĻŦāĻžāϰāĻŋāĻ āϰā§āĻā§āϰ āĻāϤāĻŋāĻšāĻžāϏ āĻ āĻāĻžāύāĻž |
| Allergy History | Not documented | āĻ ā§āϝāĻžāϞāĻžāϰā§āĻāĻŋāϰ āϤāĻĨā§āϝ āύā§āĻ |
| Menopausal History | Not documented | Menopause-āϏāĻāĻā§āϰāĻžāύā§āϤ āĻāϤāĻŋāĻšāĻžāϏ āύā§āĻ |
| Smoking/Alcohol History | Not documented | āĻā§āύ⧠āϤāĻĨā§āϝ āύā§āĻ |
Confidence: 0.99 â Documentation assessment.
History that must be obtained
āĻĒā§āϰāĻĨāĻŽāϤ, Nocturia āĻāϤāĻĻāĻŋāύ āϧāϰ⧠āĻšāĻā§āĻā§, āϰāĻžāϤ⧠āĻāϤāĻŦāĻžāϰ āĻĒā§āϰāϏā§āϰāĻžāĻŦ āĻšāϝāĻŧ, āĻā§āĻŦāĻžāϞāĻžāĻĒā§āĻĄāĻŧāĻž, Urgency, Urinary Incontinence āĻŦāĻž āĻĒā§āϰāϏā§āϰāĻžāĻŦ āĻāĻāĻā§ āϝāĻžāĻāϝāĻŧāĻžāϰ āϏāĻŽāϏā§āϝāĻž āĻāĻā§ āĻāĻŋ āύāĻž āĻāĻžāύāϤ⧠āĻšāĻŦā§āĨ¤
āĻĻā§āĻŦāĻŋāϤā§āϝāĻŧāϤ, āĻāĻžāĻāϧā§āϰ āĻŦā§āϝāĻĨāĻžāϰ āϏāĻā§āĻā§ āϏāĻāĻžāϞ⧠āĻāϝāĻŧā§āύā§āĻ āĻļāĻā§āϤ āĻšāϝāĻŧā§ āĻĨāĻžāĻāĻž, āĻĢā§āϞāĻž, āĻšāĻžāϤā§āϰ āĻā§āĻ āĻāϝāĻŧā§āύā§āĻā§ āĻŦā§āϝāĻĨāĻž āĻ āĻĨāĻŦāĻž āĻāĻā§ Rheumatoid Arthritis-āĻāϰ āĻāĻŋāĻāĻŋā§āϏāĻžāϰ āĻāϤāĻŋāĻšāĻžāϏ āĻāĻā§ āĻāĻŋ āύāĻž āĻāĻžāύāϤ⧠āĻšāĻŦā§āĨ¤
āϤā§āϤā§āϝāĻŧāϤ, āĻĒā§āϰā§āĻŦā§āϰ DMARD āĻŦā§āϝāĻŦāĻšāĻžāϰ, Methotrexate treatment history, Kidney Disease, Tuberculosis, Hepatitis B/C, Cardiovascular Disease āĻāĻŦāĻ āĻŦāϰā§āϤāĻŽāĻžāύ āĻāώā§āϧā§āϰ āϤāĻžāϞāĻŋāĻāĻž āĻāĻžāύāϤ⧠āĻšāĻŦā§āĨ¤
Confidence: 0.96 â Recommended clinical history.
4. O/E â On Examination
āĻĒā§āϰā§āϏāĻā§āϰāĻŋāĻĒāĻļāύ⧠āϤāĻŋāύāĻāĻŋ āĻĒāϰā§āϝāĻŦā§āĻā§āώāĻŖ āϞā§āĻāĻž āĻšāϝāĻŧā§āĻā§āĨ¤
4.1 Blood Pressure: 110/70 mmHg
Interpretation: āĻĒā§āϰāĻĻāϤā§āϤ āϰāĻā§āϤāĻāĻžāĻĒ āϏā§āĻŦāĻžāĻāĻžāĻŦāĻŋāĻ āϏā§āĻŽāĻžāϰ āĻŽāϧā§āϝā§āĨ¤ āϤāĻŦā§ āĻŦāϝāĻŧāϏā§āĻ āϰā§āĻā§āϰ Orthostatic Hypotension āĻāĻā§ āĻāĻŋ āύāĻž āϝāĻžāĻāĻžāĻ āĻāϰāĻž āĻāĻĒāĻāĻžāϰā§, āĻŦāĻŋāĻļā§āώāϤ āĻŽāĻžāĻĨāĻž āĻā§āϰāĻž āĻŦāĻž āĻĒāĻĄāĻŧā§ āϝāĻžāĻāϝāĻŧāĻžāϰ āĻāϤāĻŋāĻšāĻžāϏ āĻĨāĻžāĻāϞā§āĨ¤
Confidence: 0.96
4.2 Pulse: 96 bpm
Interpretation: āĻāĻāĻŋ āĻĒā§āϰāĻžāĻĒā§āϤāĻŦāϝāĻŧāϏā§āĻāĻĻā§āϰ āĻĒā§āϰāĻāϞāĻŋāϤ resting pulse range-āĻāϰ āĻŽāϧā§āϝ⧠āϰāϝāĻŧā§āĻā§, āϝāĻĻāĻŋāĻ āĻāĻā§āĻ āϏā§āĻŽāĻžāϰ āĻāĻžāĻāĻžāĻāĻžāĻāĻŋāĨ¤ āĻŦā§āϝāĻĨāĻž, āĻāĻĻā§āĻŦā§āĻ, āĻā§āĻŦāϰ āĻŦāĻž āĻ āύā§āϝāĻžāύā§āϝ āĻāĻžāϰāĻŖā§ Pulse āĻŦā§āĻĄāĻŧā§ āϝā§āϤ⧠āĻĒāĻžāϰā§āĨ¤
Confidence: 0.97
4.3 SpOâ: 99%
Interpretation: āĻĒā§āϰāĻĻāϤā§āϤ āĻ āĻā§āϏāĻŋāĻā§āύ āϏā§āϝāĻžāĻā§āϰā§āĻļāύ āϏā§āĻŦāĻžāĻāĻžāĻŦāĻŋāĻāĨ¤ āϤāĻŦā§ āϏā§āĻŦāĻžāĻāĻžāĻŦāĻŋāĻ SpOâ āĻĻā§āĻŦāĻžāϰāĻž āĻļā§āĻŦāĻžāϏāϤāύā§āϤā§āϰā§āϰ āϏāĻāĻā§āϰāĻŽāĻŖ āϏāĻŽā§āĻĒā§āϰā§āĻŖāĻāĻžāĻŦā§ āĻŦāĻžāĻĻ āĻĻā§āĻāϝāĻŧāĻž āϝāĻžāϝāĻŧ āύāĻžāĨ¤
Confidence: 0.98
Missing examinations
Abdominal Examination, Costovertebral Angle Tenderness, Joint Examination, Neurological Examination, Temperature, Respiratory Examination āĻāĻŦāĻ Post-Void Residual Assessment āύāĻĨāĻŋāĻā§āĻā§āϤ āύā§āĻāĨ¤
Confidence: 0.99
5. Doctor-Advised Investigations â āĻĒāϰā§āĻā§āώāĻžāϰ āϤāĻžāϞāĻŋāĻāĻž āĻ āĻŦā§āϝāĻžāĻā§āϝāĻž
āĻĒā§āϰā§āϏāĻā§āϰāĻŋāĻĒāĻļāύā§āϰ AD āĻ āĻāĻļā§ āĻĒāĻžāĻāĻāĻāĻŋ āĻĒāϰā§āĻā§āώāĻž āϰāϝāĻŧā§āĻā§āĨ¤
āĻā§āϰā§āϤā§āĻŦāĻĒā§āϰā§āĻŖ: āĻāĻāĻžāύ⧠āĻĒāϰā§āĻā§āώāĻžāϰ āύāĻŋāϰā§āĻĻā§āĻļ āĻāĻā§, āĻāĻŋāύā§āϤ⧠āĻā§āύ⧠āĻĒāϰā§āĻā§āώāĻžāϰ āĻĢāϞāĻžāĻĢāϞ āĻŦāĻž āϰāĻŋāĻĒā§āϰā§āĻ āϏāĻāϝā§āĻā§āϤ āύā§āĻāĨ¤
| No. | Investigation | āĻŦāĻžāĻāϞāĻž āĻ āϰā§āĻĨ | Why Important |
|---|---|---|---|
| 1 | S. Creatinine | āϰāĻā§āϤ⧠āĻā§āϰāĻŋāϝāĻŧā§āĻāĻŋāύāĻŋāύ | āĻāĻŋāĻĄāύāĻŋāϰ āĻāĻžāϰā§āϝāĻāĻžāϰāĻŋāϤāĻž āĻŽā§āϞā§āϝāĻžāϝāĻŧāύ |
| 2 | RA Factor | āϰāĻŋāĻāĻŽāĻžāĻāϝāĻŧā§āĻĄ āĻĢā§āϝāĻžāĻā§āĻāϰ | āĻĒā§āϰāĻĻāĻžāĻšāĻāύāĻŋāϤ āĻŦāĻžāϤāϰā§āĻā§āϰ āĻŽā§āϞā§āϝāĻžāϝāĻŧāύ⧠āϏāĻšāĻžāϝāĻŧāĻ |
| 3 | Urine R/M/E | āĻĒā§āϰāϏā§āϰāĻžāĻŦā§āϰ āϰā§āĻāĻŋāύ āĻ āĻŽāĻžāĻāĻā§āϰā§āϏā§āĻā§āĻĒāĻŋāĻ āĻĒāϰā§āĻā§āώāĻž | Pyuria, Hematuria āĻ āĻ āύā§āϝāĻžāύā§āϝ āĻ āϏā§āĻŦāĻžāĻāĻžāĻŦāĻŋāĻāϤāĻž |
| 4 | RBS | Random Blood Sugar | āϰāĻā§āϤ⧠āĻā§āϞā§āĻā§āĻā§āϰ āĻŽāĻžāϤā§āϰāĻž |
| 5 | USG of L/A | āϤāϞāĻĒā§āĻā§āϰ āĻāϞā§āĻā§āϰāĻžāϏāύā§āĻā§āϰāĻžāĻĢāĻŋ | āĻŽā§āϤā§āϰāĻĨāϞāĻŋ āĻ āĻĒā§āϞāĻāĻŋāĻ āĻ āĻā§āĻāϏāĻŽā§āĻšā§āϰ āĻŽā§āϞā§āϝāĻžāϝāĻŧāύ |
Confidence: 0.99 â Prescription transcription.
Investigation-wise clinical interpretation
1. Serum Creatinine: āϰā§āĻā§āϰ āĻŦāϝāĻŧāϏ ā§Žā§Ģ āĻŦāĻāϰāĨ¤ Nitrofurantoin, Mirogabalin āĻāĻŦāĻ āĻ āύā§āϝāĻžāύā§āϝ āĻāώā§āϧā§āϰ āύāĻŋāϰāĻžāĻĒāĻĻ āĻŦā§āϝāĻŦāĻšāĻžāϰ āĻŽā§āϞā§āϝāĻžāϝāĻŧāύā§āϰ āĻāύā§āϝ Creatinine-āĻāϰ āĻĒāĻžāĻļāĻžāĻĒāĻžāĻļāĻŋ eGFR āĻĻāϰāĻāĻžāϰāĨ¤ Creatinine āĻāĻāĻž āϝāĻĨā§āώā§āĻ āύāϝāĻŧāĨ¤
Confidence: 0.99
2. Rheumatoid Factor: RA Factor positive āĻšāϞ⧠Rheumatoid Arthritis-āĻāϰ āϏāĻŽā§āĻāĻžāĻŦāύāĻž āĻŦāĻžāĻĄāĻŧāϤ⧠āĻĒāĻžāϰā§, āĻāĻŋāύā§āϤ⧠āĻāĻāĻŋ āĻāĻāĻž āϰā§āĻ āύāĻŋāĻļā§āĻāĻŋāϤ āĻāϰ⧠āύāĻžāĨ¤ Negative āĻšāϞā§āĻ RA āϏāĻŽā§āĻĒā§āϰā§āĻŖ āĻŦāĻžāĻĻ āϝāĻžāϝāĻŧ āύāĻžāĨ¤ Clinical Synovitis, Anti-CCP āĻāĻŦāĻ Inflammatory Markers āĻā§āϰā§āϤā§āĻŦāĻĒā§āϰā§āĻŖāĨ¤
Confidence: 0.99
3. Urine R/M/E: āĻĒā§āϰāϏā§āϰāĻžāĻŦā§ WBC, RBC, Bacteria, Protein, Glucose āĻāϤā§āϝāĻžāĻĻāĻŋ āĻĻā§āĻāĻž āϝāĻžāϝāĻŧāĨ¤ āϤāĻŦā§ āĻŦāϝāĻŧāϏā§āĻ āϰā§āĻā§āϰ āĻĒā§āϰāϏā§āϰāĻžāĻŦā§ āĻŦā§āϝāĻžāĻāĻā§āϰāĻŋāϝāĻŧāĻž āĻĒāĻžāĻāϝāĻŧāĻž āĻā§āϞā§āĻ Symptomatic UTI āĻŦāϞāĻž āϝāĻžāϝāĻŧ āύāĻžāĨ¤
Confidence: 0.99
4. RBS: Diabetes āĻŦāĻž Hyperglycemia āĻĨāĻžāĻāϞ⧠Polyuria āĻ Nocturia āĻšāϤ⧠āĻĒāĻžāϰā§āĨ¤
Confidence: 0.98
5. USG of Lower Abdomen: Bladder abnormality, bladder stone āĻāĻŦāĻ āĻ āύā§āϝāĻžāύā§āϝ pelvic pathology āĻŽā§āϞā§āϝāĻžāϝāĻŧāύ⧠āϏāĻšāĻžāϝāĻŧāĻāĨ¤ āϤāĻŦā§ Post-Void Residual (PVR) āĻĒāϰāĻŋāĻŽāĻžāĻĒ āĻāϞāĻžāĻĻāĻžāĻāĻžāĻŦā§ āĻāϞā§āϞā§āĻ āĻŦāĻž āϏāĻŽā§āĻĒāύā§āύ āĻāϰāϤ⧠āĻšāĻŦā§āĨ¤
Confidence: 0.96
Additional investigations I would consider
āϰā§āĻā§āϰ āĻāϤāĻŋāĻšāĻžāϏ āĻ āĻļāĻžāϰā§āϰāĻŋāĻ āĻĒāϰā§āĻā§āώāĻžāϰ āĻāĻŋāϤā§āϤāĻŋāϤā§:
- Urine Culture and Sensitivity â Symptomatic UTI āϏāύā§āĻĻā§āĻš āĻšāϞā§āĨ¤
- CBC with Differential Count â āϏāĻāĻā§āϰāĻŽāĻŖ āĻ āϰāĻā§āϤāϏā§āĻŦāϞā§āĻĒāϤāĻž āĻŽā§āϞā§āϝāĻžāϝāĻŧāύā§āĨ¤
- ESR, CRP â Inflammatory arthritis āĻŦāĻž PMR āϏāύā§āĻĻā§āĻš āĻšāϞā§āĨ¤
- Anti-CCP Antibody â RA evaluation-āĻāĨ¤
- HbA1c â Diabetes-āĻāϰ āϏāĻŽā§āĻāĻžāĻŦāύāĻž āĻŽā§āϞā§āϝāĻžāϝāĻŧāύā§āĨ¤
- Serum Electrolytes â āĻĒā§āϰāϝāĻŧā§āĻāύ āĻ āύā§āϏāĻžāϰā§āĨ¤
- eGFR and calculated Creatinine Clearance â Renal drug dosing-āĻāϰ āĻāύā§āϝāĨ¤
- Post-Void Residual and Bladder Diary â Nocturia/OAB āĻŽā§āϞā§āϝāĻžāϝāĻŧāύā§āĨ¤
- LFT, TB screening, Hepatitis B/C screening āĻ Lipid Profile â Tofacitinib treatment-āĻāϰ āϝāĻĨāĻžāϰā§āĻĨāϤāĻž āϝāĻžāĻāĻžāĻ āĻāĻŦāĻ āĻĒāϰā§āϝāĻŦā§āĻā§āώāĻŖā§āϰ āĻāύā§āϝāĨ¤
Confidence: 0.94
AUA/SUFU 2024 OAB guideline āĻ āύā§āϝāĻžāϝāĻŧā§ History, Physical Examination āĻāĻŦāĻ Urinalysis āĻĒā§āϰāĻžāĻĨāĻŽāĻŋāĻ āĻŽā§āϞā§āϝāĻžāϝāĻŧāύā§āϰ āĻ āĻāĻļāĨ¤ āĻĒā§āϰāϝāĻŧā§āĻāύ āĻ āύā§āϝāĻžāϝāĻŧā§ PVR āĻ Bladder Diary āĻāϰāĻž āĻšāϝāĻŧāĨ¤
6. Disease Definition, Etiology & Pathophysiology
6.1 Nocturia â āϰāĻžāϤ⧠āĻĒā§āϰāϏā§āϰāĻžāĻŦā§āϰ āĻāύā§āϝ āĻā§āĻŽ āĻāĻžāĻāĻž
Definition: āĻā§āĻŽā§āϰ āĻĒā§āϰāϧāĻžāύ āϏāĻŽāϝāĻŧā§ āĻĒā§āϰāϏā§āϰāĻžāĻŦ āĻāϰāĻžāϰ āĻāύā§āϝ āĻāĻ āĻŦāĻž āĻāĻāĻžāϧāĻŋāĻāĻŦāĻžāϰ āĻā§āĻŽ āĻĨā§āĻā§ āĻāĻ āĻžāĻā§ Nocturia āĻŦāϞāĻž āĻšāϝāĻŧāĨ¤
āϏāĻŽā§āĻāĻžāĻŦā§āϝ āĻāĻžāϰāĻŖāĻā§āϞā§āϰ āĻŽāϧā§āϝ⧠āϰāϝāĻŧā§āĻā§:
- Nocturnal Polyuria
- Overactive Bladder
- Urinary Tract Infection
- Diabetes Mellitus
- Reduced Functional Bladder Capacity
- Incomplete Bladder Emptying
- Sleep Disorders
- Heart Failure-associated nocturnal diuresis
Patient-specific confidence in the underlying cause: 0.50
6.2 Overactive Bladder (OAB) â āĻ āϤāĻŋāϏāĻā§āϰāĻŋāϝāĻŧ āĻŽā§āϤā§āϰāĻĨāϞāĻŋ
Definition: Urinary Urgency āĻĒā§āϰāϧāĻžāύ āĻāĻĒāϏāϰā§āĻ āĻšāĻŋāϏā§āĻŦā§ āĻāĻĒāϏā§āĻĨāĻŋāϤ āĻĨāĻžāĻā§, āϏāĻžāϧāĻžāϰāĻŖāϤ Frequency āĻ Nocturia-āϏāĻš; Urgency Incontinence āĻĨāĻžāĻāϤ⧠āĻĒāĻžāϰ⧠āĻ āĻĨāĻŦāĻž āύāĻžāĻ āĻĨāĻžāĻāϤ⧠āĻĒāĻžāϰā§āĨ¤ UTI āĻŦāĻž āĻ āύā§āϝ āϏā§āϏā§āĻĒāώā§āĻ pathology āĻĻā§āĻŦāĻžāϰāĻž āĻāĻĒāϏāϰā§āĻ āĻŦā§āϝāĻžāĻā§āϝāĻž āĻāϰāĻž āĻā§āϞ⧠idiopathic OAB āύāĻŋāϰā§āĻŖāϝāĻŧ āĻāϰāĻž āĻāĻāĻŋāϤ āύāϝāĻŧāĨ¤
Pathophysiology: Detrusor muscle āĻ bladder sensory signaling-āĻāϰ āĻ āϏā§āĻŦāĻžāĻāĻžāĻŦāĻŋāĻāϤāĻž āĻĒā§āϰāϏā§āϰāĻžāĻŦā§āϰ āϤā§āĻŦā§āϰ āĻŦā§āĻā§āϰ āϏāĻā§āĻā§ āϏāĻŽā§āĻĒāϰā§āĻāĻŋāϤ āĻšāϤ⧠āĻĒāĻžāϰā§āĨ¤
āĻāĻ āϰā§āĻā§āϰ āĻā§āώā§āϤā§āϰā§: Mirabegron āĻ Flavoxate āĻŦā§āϝāĻŦāĻšāĻžāϰ OAB-āĻāĻžāϤā§āϝāĻŧ āĻāĻĒāϏāϰā§āĻā§āϰ āĻāĻŋāĻāĻŋā§āϏāĻžāϰ āĻāĻā§āĻāĻŋāϤ āĻĻā§āϝāĻŧ, āĻāĻŋāύā§āϤ⧠Urgency āϞā§āĻāĻž āύā§āĻāĨ¤
Confidence in suspected OAB: 0.56
6.3 Urinary Tract Infection (UTI) â āĻŽā§āϤā§āϰāύāĻžāϞā§āϰ āϏāĻāĻā§āϰāĻŽāĻŖ
Definition: āĻŽā§āϤā§āϰāϤāύā§āϤā§āϰ⧠āĻā§āĻŦāĻžāĻŖā§āĻāύāĻŋāϤ āϏāĻāĻā§āϰāĻŽāĻŖā§āϰ āϏāĻā§āĻā§ āϏāĻžāĻŽāĻā§āĻāϏā§āϝāĻĒā§āϰā§āĻŖ Clinical Symptoms āĻāĻŦāĻ āĻĒā§āϰāĻžāϏāĻā§āĻāĻŋāĻ āĻĒāϰā§āĻā§āώāĻžāϰ āĻĢāϞāĻžāĻĢāϞ āĻĨāĻžāĻāϞ⧠Symptomatic UTI āύāĻŋāϰā§āĻŖāϝāĻŧ āĻāϰāĻž āĻšāϝāĻŧāĨ¤
Pathophysiology: āϏāĻžāϧāĻžāϰāĻŖāϤ Enteric Bacteria, āĻŦāĻŋāĻļā§āώāϤ Escherichia coli, āĻŽā§āϤā§āϰāύāĻžāϞ⧠āĻĻāĻŋāϝāĻŧā§ āĻĒā§āϰāĻŦā§āĻļ āĻāϰ⧠āϏāĻāĻā§āϰāĻŽāĻŖ āĻāĻāĻžāϝāĻŧāĨ¤
āĻāĻ āϰā§āĻā§āϰ āĻā§āώā§āϤā§āϰā§: Nitrofurantoin āĻĻā§āĻāϝāĻŧāĻž āĻšāϝāĻŧā§āĻā§, āϝāĻž UTI āĻāĻŋāĻāĻŋā§āϏāĻžāϰ āĻāώā§āϧāĨ¤ āĻāĻŋāύā§āϤ⧠Nocturia āĻāĻžāĻĄāĻŧāĻž Dysuria, Suprapubic Pain, Fever āĻ āĻĨāĻŦāĻž Urine Culture result āύā§āĻāĨ¤
āϏā§āϤāϰāĻžāĻ Confirmed UTI āϞā§āĻāĻž āϝāĻžāĻŦā§ āύāĻžāĨ¤
Confidence in possible UTI: 0.43
IDSA 2019 guideline āĻ āύā§āϝāĻžāϝāĻŧā§ āĻŦāϝāĻŧāϏā§āĻ āϰā§āĻā§āϰ Asymptomatic Bacteriuria āϏāĻžāϧāĻžāϰāĻŖāϤ antibiotic āĻĻāĻŋāϝāĻŧā§ āĻāĻŋāĻāĻŋā§āϏāĻž āĻāϰāĻž āĻāĻāĻŋāϤ āύāϝāĻŧ, āύāĻŋāϰā§āĻĻāĻŋāώā§āĻ āĻŦā§āϝāϤāĻŋāĻā§āϰāĻŽ āĻāĻžāĻĄāĻŧāĻžāĨ¤
6.4 Rheumatoid Arthritis (RA) â āϰāĻŋāĻāĻŽāĻžāĻāϝāĻŧā§āĻĄ āĻāϰā§āĻĨā§āϰāĻžāĻāĻāĻŋāϏ
Definition: āĻĻā§āϰā§āĻāϏā§āĻĨāĻžāϝāĻŧā§ Systemic Autoimmune Inflammatory Disease, āϝāĻž āĻĒā§āϰāϧāĻžāύāϤ Synovial Joints-āĻ āĻĒā§āϰāĻĻāĻžāĻš āϏā§āώā§āĻāĻŋ āĻāϰā§āĨ¤
Pathophysiology: Autoimmune Synovitis, Cytokine activation āĻāĻŦāĻ progressive joint damage āĻšāϤ⧠āĻĒāĻžāϰā§āĨ¤
āĻāĻ āϰā§āĻā§āϰ āĻā§āώā§āϤā§āϰā§: Tofacitinib āĻŦā§āϝāĻŦāĻšāĻžāϰ āĻ RA Factor test-āĻāϰ āύāĻŋāϰā§āĻĻā§āĻļ RA-āϏāĻāĻā§āϰāĻžāύā§āϤ āϏāύā§āĻĻā§āĻš āĻŦāĻž āĻĒā§āϰā§āĻŦā§āϰ āĻāĻŋāĻāĻŋā§āϏāĻžāϰ āϏāĻŽā§āĻāĻžāĻŦāύāĻž āϤā§āϰāĻŋ āĻāϰā§āĨ¤ āĻāĻŋāύā§āϤ⧠Clinical Synovitis, Small-Joint Involvement, Morning Stiffness, RF result, Anti-CCP āĻāĻŦāĻ āĻĒā§āϰā§āĻŦā§āϰ RA diagnosis āύā§āĻāĨ¤
Conclusion: RA āĻāĻāĻāĻŋ differential diagnosis; āύāĻŋāĻļā§āĻāĻŋāϤ āϰā§āĻ āύāϝāĻŧāĨ¤
Confidence in confirmed RA: 0.25 â Insufficient evidence.
7. đŠ Prescribed Drug Analysis â MedEx āĻ āύā§āϝāĻžāϝāĻŧā§
āĻĒā§āϰā§āϏāĻā§āϰāĻŋāĻĒāĻļāύ⧠āĻŽā§āĻ ā§§ā§ĻāĻāĻŋ āĻāώā§āϧ/āĻĒā§āϰāϏā§āϤā§āϤāĻŋ āϰāϝāĻŧā§āĻā§āĨ¤ āĻĒā§āϰāϤāĻŋāĻāĻŋ āĻĒā§āĻĨāĻāĻāĻžāĻŦā§ MedEx Bangladesh-āĻāϰ āϤāĻĨā§āϝā§āϰ āϏāĻā§āĻā§ āĻŽāĻŋāϞāĻŋāϝāĻŧā§ āĻŦāĻŋāĻļā§āϞā§āώāĻŖ āĻāϰāĻž āĻšāϞā§āĨ¤
Table 1: Original Prescription â Exact Drug Review
| No. | Prescribed Medicine | Generic | Written Dose | Written Duration |
|---|---|---|---|---|
| 1 | Nintoin SR 100 mg | Nitrofurantoin | 1+0+1 | 7 days |
| 2 | Uroza 200 mg | Flavoxate | 1+0+1 | 1 month |
| 3 | M-Beg 25 mg | Mirabegron | 1+0+0 | 1 month |
| 4 | Sudac 200 mg | Sulindac | 1+0+1 | 10 days |
| 5 | Tofatin XR 11 mg | Tofacitinib | 0+0+1 | 20 days |
| 6 | Merolin 5 mg* | Mirogabalin | 1+0+1 | 15 days |
| 7 | Zo-MUPS 40 mg | Esomeprazole | 1+0+1 | 15 days |
| 8 | Gavirad Suspension* | Alginate combination | 2 teaspoons à 3 | 15 days |
| 9 | Brofex TS | Dextromethorphan Polistirex | 2 teaspoons à 3 | 15 days |
| 10 | Voligel Max 2% | Diclofenac Sodium | Apply twice daily | Duration not specified |
*Merolin āĻ Gavirad: āĻšāĻžāϤā§āϰ āϞā§āĻāĻž āĻ MedEx-āĻāϰ brand name āĻŽāĻŋāϞāĻŋāϝāĻŧā§ āĻĒāĻĄāĻŧāĻž āĻšāϝāĻŧā§āĻā§āĨ¤ āĻāώā§āϧā§āϰ āĻĒā§āϝāĻžāĻā§āĻ āĻĻāĻŋāϝāĻŧā§ āύāĻŋāĻļā§āĻāĻŋāϤ āĻāϰāĻž āĻāĻāĻŋāϤāĨ¤
Transcription confidence: 0.94; Merolin/Gavirad identification confidence: 0.83.
7.1 Medicine No. 1 â Nintoin SR 100 mg
1. Generic Name: Nitrofurantoin â āύāĻžāĻāĻā§āϰā§āĻĢāĻŋāĻāϰāĻžāύāĻā§āĻāύāĨ¤
2. Brand Name: Nintoin SR 100 mg.
3. MedEx Alternate Brands: Nitrobac SR 100 mg, Nitrofur SR 100 mg.
4. MedEx Therapeutic Class: Systemic Urinary Anti-infective.
5. Pharmacological Class: Nitrofuran antibacterial antibiotic.
6. Purpose: āĻŽā§āϤā§āϰāύāĻžāϞā§āϰ āĻŦā§āϝāĻžāĻāĻā§āϰāĻŋāϝāĻŧāĻžāĻāύāĻŋāϤ āϏāĻāĻā§āϰāĻŽāĻŖā§āϰ āĻāĻŋāĻāĻŋā§āϏāĻžāĨ¤
7. Why prescribed in this patient: Nocturia-āϰ āϏāĻā§āĻā§ UTI āϏāύā§āĻĻā§āĻš āĻāϰ⧠āĻĄāĻžāĻā§āϤāĻžāϰ āĻāώā§āϧāĻāĻŋ āĻĻāĻŋāϝāĻŧā§ āĻĨāĻžāĻāϤ⧠āĻĒāĻžāϰā§āύāĨ¤ āϤāĻŦā§ UTI āύāĻŋāĻļā§āĻāĻŋāϤ āĻšāĻāϝāĻŧāĻžāϰ āϤāĻĨā§āϝ āύā§āĻāĨ¤
8. Side Effects: Nausea, vomiting, headache, gastrointestinal upset; āĻŦāĻŋāϰāϞ āĻāĻŋāύā§āϤ⧠āĻā§āϰā§āϤā§āĻŦāĻĒā§āϰā§āĻŖ Pulmonary Toxicity, Hepatotoxicity āĻ Peripheral NeuropathyāĨ¤
9. MedEx Link: Nintoin SR â MedEx
10. Price & Other Composition: Unit ā§ŗ23; Strip ā§ŗ230āĨ¤ āĻāĻāĻ brand-āĻāϰ 100 mg conventional tablet, 50 mg capsule āĻāĻŦāĻ suspension āϰāϝāĻŧā§āĻā§āĨ¤
11. Mechanism: Bacterial proteins āĻ āĻ āύā§āϝāĻžāύā§āϝ āĻā§āϰā§āϤā§āĻŦāĻĒā§āϰā§āĻŖ macromolecules-āĻāϰ āĻāĻžāϰā§āϝāĻāĻžāϰāĻŋāϤāĻž āĻŦā§āϝāĻžāĻšāϤ āĻāϰā§āĨ¤
12. Indications: Susceptible organisms āĻĻā§āĻŦāĻžāϰāĻž āϏā§āώā§āĻ Lower UTIāĨ¤
13. Interactions & Contraindications: Magnesium Trisilicate antacid āĻ Probenecid-āĻāϰ āϏāĻā§āĻā§ interaction āĻšāϤ⧠āĻĒāĻžāϰā§āĨ¤ Significant renal impairment āĻāĻŦāĻ Nitrofurantoin allergy āĻĨāĻžāĻāϞ⧠āĻŦā§āϝāĻŦāĻšāĻžāϰ āĻ āύā§āĻĒāϝā§āĻā§āϤ āĻšāϤ⧠āĻĒāĻžāϰā§āĨ¤
14. Precautions: Renal function āϝāĻžāĻāĻžāĻ āĻāϰā§āϰāĻŋāĨ¤ Nitrofurantoin suspected Pyelonephritis āĻŦāĻž Urosepsis-āĻāϰ āĻāĻĒāϝā§āĻā§āϤ āĻāĻŋāĻāĻŋā§āϏāĻž āύāϝāĻŧāĨ¤
15. Dosage & Administration: Prescription: 100 mg twice daily for 7 daysāĨ¤ MedEx-āĻ SR formulation-āĻāϰ āĻāύā§āϝ 100 mg every 12 hours āĻāϞā§āϞā§āĻ āĻāĻā§āĨ¤ āĻāĻžāĻŦāĻžāϰā§āϰ āϏāĻā§āĻā§ āĻā§āϰāĻšāĻŖ āĻāϰāĻž āĻšāϝāĻŧāĨ¤
16. Pregnancy & Lactation: āĻāϰā§āĻāĻžāĻŦāϏā§āĻĨāĻžāϰ āĻļā§āώ āĻĒāϰā§āϝāĻžāϝāĻŧā§ āĻāĻŦāĻ āύāĻŦāĻāĻžāϤāĻāĻā§ āĻŦā§āĻā§āϰ āĻĻā§āϧ āĻāĻžāĻāϝāĻŧāĻžāύā§āϰ āύāĻŋāϰā§āĻĻāĻŋāώā§āĻ āĻĒāϰāĻŋāϏā§āĻĨāĻŋāϤāĻŋāϤ⧠āĻā§āϰā§āϤā§āĻŦāĻĒā§āϰā§āĻŖ āϏāϤāϰā§āĻāϤāĻž āϰāϝāĻŧā§āĻā§; āĻŦāϰā§āϤāĻŽāĻžāύ āϰā§āĻā§āϰ āĻŦāϝāĻŧāϏā§āϰ āĻāĻžāϰāĻŖā§ āĻŦāĻŋāώāϝāĻŧāĻāĻŋ clinically applicable āύāϝāĻŧāĨ¤
Clinical Verdict: āĻāώā§āϧā§āϰ UTI-āϏāĻāĻā§āϰāĻžāύā§āϤ āĻŦā§āϝāĻŦāĻšāĻžāϰ āϏāĻ āĻŋāĻ āĻšāϞā§āĻ āϰā§āĻā§āϰ āĻā§āώā§āϤā§āϰ⧠infection confirmation āĻāĻŦāĻ eGFR āϝāĻžāĻāĻžāĻ āĻ āĻĒāϰāĻŋāĻšāĻžāϰā§āϝāĨ¤
Confidence: 0.98 â Drug identification; 0.44 â Patient-specific indication.
7.2 Medicine No. 2 â Uroza 200 mg
1. Generic: Flavoxate Hydrochloride.
2. Brand: Uroza 200 mg.
3. Alternate Brands: Urilax 200 mg, Flavox 200 mg.
4. MedEx Therapeutic Class: BPH/Urinary Retention/Urinary Incontinence.
5. Pharmacological Class: Urinary Antispasmodic; antimuscarinic properties āϰāϝāĻŧā§āĻā§āĨ¤
6. Purpose: Bladder spasm āĻ urinary urgency/frequency-āĻāĻžāϤā§āϝāĻŧ āĻāĻĒāϏāϰā§āĻ āĻāĻŽāĻžāύā§āĨ¤
7. Why prescribed: āϰā§āĻā§āϰ Nocturia-āϰ āϏāĻā§āĻā§ bladder irritation āĻŦāĻž storage symptoms āϏāύā§āĻĻā§āĻš āĻāϰāĻž āĻšāϝāĻŧā§ āĻĨāĻžāĻāϤ⧠āĻĒāĻžāϰā§āĨ¤
8. Side Effects: Dry mouth, constipation, dizziness, blurred vision, confusion, palpitations āĻ urinary retentionāĨ¤
9. MedEx Link: Uroza 200 mg â MedEx
10. Price & Composition: Unit ā§ŗ18; Strip ā§ŗ180āĨ¤ Flavoxate 100 mg āĻ āύā§āϝ brand-āĻ āĻĒāĻžāĻāϝāĻŧāĻž āϝāĻžāϝāĻŧāĨ¤
11. Mechanism: āĻŽā§āϤā§āϰāĻĨāϞāĻŋāϰ smooth-muscle tone āĻāĻŦāĻ muscarinic signaling āĻāĻŽāĻŋāϝāĻŧā§ āĻāĻĒāϏāϰā§āĻ āĻĒā§āϰāĻļāĻŽāύ⧠āϏāĻšāĻžāϝāĻŧāϤāĻž āĻāϰā§āĨ¤
12. Indications: Dysuria, urgency, nocturia, urinary frequency āĻāĻŦāĻ cystitis-āϏāĻāĻā§āϰāĻžāύā§āϤ bladder discomfort-āĻāϰ symptomatic reliefāĨ¤
13. Interaction & Contraindications: Obstructive Uropathy, gastrointestinal obstruction āĻāĻŦāĻ urinary retention-āϏāĻāĻā§āϰāĻžāύā§āϤ āĻĒāϰāĻŋāϏā§āĻĨāĻŋāϤāĻŋāϤ⧠āĻā§āϰā§āϤā§āĻŦāĻĒā§āϰā§āĻŖ āϏāϤāϰā§āĻāϤāĻž/contraindication āϰāϝāĻŧā§āĻā§āĨ¤
14. Precautions: ā§Žā§Ģ āĻŦāĻāϰ āĻŦāϝāĻŧāϏ⧠Anticholinergic Adverse Effects, confusion, glaucoma-related risks āĻ falls āĻŦāĻŋāĻŦā§āĻāύāĻž āĻāϰāϤ⧠āĻšāĻŦā§āĨ¤
15. Dosage: Prescription āĻ āύā§āϝāĻžāϝāĻŧā§ 200 mg twice daily for one monthāĨ¤ MedEx-āĻ āϏāĻžāϧāĻžāϰāĻŖāĻāĻžāĻŦā§ 100â200 mg āĻĻāĻŋāĻ¨ā§ ā§Šâā§Ē āĻŦāĻžāϰ āĻŦāϰā§āĻŖāĻŋāϤ āĻšāϞā§āĻ āϰā§āĻā§āϰ āĻŦāϝāĻŧāϏ āĻ tolerability āĻ āύā§āϝāĻžāϝāĻŧā§ āϏāĻŋāĻĻā§āϧāĻžāύā§āϤ āύāĻŋāϤ⧠āĻšāϝāĻŧāĨ¤
16. Pregnancy & Lactation: āĻĒāϰā§āϝāĻžāĻĒā§āϤ āϤāĻĨā§āϝ āϏā§āĻŽāĻŋāϤ; āĻĒā§āϰāϝāĻŧā§āĻāύ āĻšāϞ⧠āĻāĻŋāĻāĻŋā§āϏāĻā§āϰ āĻŽā§āϞā§āϝāĻžāϝāĻŧāύ āĻĻāϰāĻāĻžāϰāĨ¤ āĻāĻ āϰā§āĻā§āϰ āĻā§āώā§āϤā§āϰ⧠āĻĒā§āϰāϝā§āĻā§āϝ āύāϝāĻŧāĨ¤
Clinical Verdict: Nocturia-āϰ symptomatic management-āĻāϰ āϏāĻā§āĻā§ āĻŦā§āϝāĻŦāĻšāĻžāϰ āϏāĻžāĻŽāĻā§āĻāϏā§āϝāĻĒā§āϰā§āĻŖāĨ¤ āϤāĻŦā§ PVR āĻ cognitive assessment āĻā§āϰā§āϤā§āĻŦāĻĒā§āϰā§āĻŖāĨ¤
Confidence: 0.98 â Pharmacology; 0.72 â Intended symptom target.
7.3 Medicine No. 3 â M-Beg 25 mg
1. Generic: Mirabegron.
2. Brand: M-Beg 25 mg XR.
3. Alternate Brands: Betmira ER 25 mg, Uroben XR 25 mg, Miragon 25 mg.
4. MedEx Therapeutic Class: BPH/Urinary Retention/Urinary Incontinence; βâ-Adrenergic Receptor Agonist.
5. Pharmacological Class: Selective Beta-3 Adrenergic Agonist.
6. Purpose: Overactive Bladder-āĻāϰ Urgency, Frequency āĻāĻŦāĻ Urge Incontinence āĻāĻŽāĻžāύā§āĨ¤
7. Why prescribed: āϰā§āĻā§āϰ Nocturia āĻ āϏāĻŽā§āĻāĻžāĻŦā§āϝ bladder storage symptoms-āĻāϰ āĻāύā§āϝāĨ¤
8. Side Effects: Increased blood pressure, tachycardia, headache āĻāĻŦāĻ urinary retentionāĨ¤
9. MedEx Link: M-Beg 25 mg â MedEx
10. Price & Composition: Unit ā§ŗ30; Strip ā§ŗ300āĨ¤ āĻāĻāĻ brand-āĻ 50 mg XR āϰāϝāĻŧā§āĻā§āĨ¤
11. Mechanism: Bladder detrusor muscle-āĻāϰ Beta-3 receptors stimulate āĻāϰ⧠bladder storage phase-āĻ relaxation āĻŦāĻžāĻĄāĻŧāĻžāϝāĻŧāĨ¤
12. Indications: Adult Overactive Bladder Syndrome.
13. Interactions & Contraindications: CYP2D6 substrate drugs-āĻāϰ exposure āĻŦāĻžāĻĄāĻŧāĻžāϤ⧠āĻĒāĻžāϰā§āĨ¤ Severe uncontrolled hypertension-āĻ contraindicatedāĨ¤
14. Precautions: BP, pulse, urinary retention āĻāĻŦāĻ renal function āĻĒāϰā§āϝāĻŦā§āĻā§āώāĻŖ āĻāϰāϤ⧠āĻšāĻŦā§āĨ¤
15. Dosage: Prescription: 25 mg once daily for one monthāĨ¤ MedEx āĻ āύā§āϝāĻžāϝāĻŧā§ āĻāĻāĻŋ āĻĒā§āϰāĻāϞāĻŋāϤ starting doseāĨ¤ XR tablet āĻā§āĻā§ āĻŦāĻž āĻāĻŋāĻŦāĻŋāϝāĻŧā§ āĻāĻžāĻāϝāĻŧāĻž āĻāĻāĻŋāϤ āύāϝāĻŧāĨ¤
16. Pregnancy & Lactation: Pregnancy āĻāĻŦāĻ breastfeeding-āĻ āϏāĻžāϧāĻžāϰāĻŖāϤ recommended āύāϝāĻŧ; āĻŦāϰā§āϤāĻŽāĻžāύ āϰā§āĻā§āϰ āĻā§āώā§āϤā§āϰ⧠āĻĒā§āϰāϝā§āĻā§āϝ āύāϝāĻŧāĨ¤
Clinical Verdict: Suspected OAB-āĻāϰ āĻāύā§āϝ āϝā§āĻā§āϤāĻŋāϏāĻāĻāϤ āϏāĻŽā§āĻāĻžāĻŦā§āϝ āĻāĻŋāĻāĻŋā§āϏāĻž, āĻāĻŋāύā§āϤ⧠OAB-āĻāϰ āĻĒā§āϰāϝāĻŧā§āĻāύā§āϝāĻŧ Urgency symptom āύāĻĨāĻŋāĻā§āĻā§āϤ āύā§āĻāĨ¤
Confidence: 0.99 â Drug identification; 0.74 â Treatment rationale.
7.4 Medicine No. 4 â Sudac 200 mg
1. Generic: Sulindac.
2. Brand: Sudac 200 mg.
3. Alternate Brands: Olida 200 mg, Lindac 200 mg, Clinorel 200 mg.
4. MedEx Therapeutic Class: Drugs for Osteoarthritis; Drugs used for Rheumatoid Arthritis; Drugs used in Gout; NSAIDs.
5. Pharmacological Class: Nonselective NSAID.
6. Purpose: Pain and inflammation relief.
7. Why prescribed: Bilateral shoulder pain āĻāĻŦāĻ Low Back Pain āĻāĻŽāĻžāύā§āϰ āĻāύā§āϝāĨ¤
8. Side Effects: Gastritis, peptic ulcer, GI bleeding, renal injury, edema, hypertension āĻ dizzinessāĨ¤
9. MedEx Link: Sudac 200 mg â MedEx
10. Price & Composition: Unit ā§ŗ10; Strip ā§ŗ100āĨ¤ āĻāĻāĻ brand-āĻ 100 mg āϰāϝāĻŧā§āĻā§āĨ¤
11. Mechanism: Active sulfide metabolite prostaglandin synthesis āĻāĻŽāĻžāϝāĻŧāĨ¤
12. Indications: RA, OA, acute painful shoulder, inflammatory musculoskeletal disorders āĻāĻŦāĻ goutāĨ¤
13. Interactions & Contraindications: Anticoagulants, antiplatelets, āĻ āύā§āϝāĻžāύā§āϝ NSAIDs, aspirin āĻāĻŦāĻ āĻāĻŋāĻā§ renal-risk medicines-āĻāϰ āϏāĻā§āĻā§ clinically significant interaction āĻšāϤ⧠āĻĒāĻžāϰā§āĨ¤ Active GI ulcer/bleeding āĻŦāĻž NSAID allergy-āϤ⧠contraindicatedāĨ¤
14. Precautions: ā§Žā§Ģ āĻŦāĻāϰ āĻŦāϝāĻŧāϏ⧠GI bleeding, kidney injury āĻāĻŦāĻ fluid retention-āĻāϰ āĻā§āĻāĻāĻŋ āĻŦā§āĻļāĻŋāĨ¤ PPI āĻŦā§āϝāĻŦāĻšāĻžāϰ āĻāϰāϞā§āĻ NSAID-āĻāϰ āϏāĻŦ āĻā§āĻāĻāĻŋ āĻĻā§āϰ āĻšāϝāĻŧ āύāĻžāĨ¤
15. Dosage: Prescription: 200 mg twice daily for 10 days = 400 mg/dayāĨ¤ MedEx-āĻ 400 mg/day āϏāϰā§āĻŦā§āĻā§āĻ āĻŽāĻžāϤā§āϰāĻž āĻšāĻŋāϏā§āĻŦā§ āĻāϞā§āϞā§āĻ āĻāĻā§āĨ¤
16. Pregnancy & Lactation: Late pregnancy-āĻ NSAIDs āĻā§āώāϤāĻŋāĻāϰ; breastfeeding-āĻāĻ āϏāϤāϰā§āĻāϤāĻž āĻĒā§āϰāϝāĻŧā§āĻāύāĨ¤ āϰā§āĻā§āϰ āĻā§āώā§āϤā§āϰ⧠āĻĒā§āϰāϝā§āĻā§āϝ āύāϝāĻŧāĨ¤
Clinical Verdict: āĻŦā§āϝāĻĨāĻž āĻāĻŽāĻžāύā§āϰ āĻāĻĻā§āĻĻā§āĻļā§āϝ āĻĒāϰāĻŋāώā§āĻāĻžāϰāĨ¤ āϤāĻŦā§ ā§Žā§Ģ āĻŦāĻāϰ āĻŦāϝāĻŧāϏ⧠āϰā§āĻā§āϰ āĻāύā§āϝ maximum listed daily dose āĻŦā§āϝāĻŦāĻšāĻžāϰ āĻāϞā§āϞā§āĻāϝā§āĻā§āϝ safety concernāĨ¤ āĻĻā§āϰā§āϤ doseârisk review āĻĒā§āϰāϝāĻŧā§āĻāύāĨ¤
Confidence: 0.99 â Dose verification; 0.97 â Geriatric safety concern.
7.5 Medicine No. 5 â Tofatin XR 11 mg
â ī¸ High-Priority Medication Safety Review
1. Generic: Tofacitinib.
2. Brand: Tofatin XR 11 mg.
3. Alternate Brands: Tofacit XR 11 mg, Tofacinix 11 mg, Xelnib XR 11 mg.
4. MedEx Therapeutic Class: Immunosuppressant.
5. Pharmacological Class: Janus Kinase Inhibitor â JAK inhibitor; targeted synthetic DMARD.
6. Purpose: āύāĻŋāϰā§āĻĻāĻŋāώā§āĻ āĻĒā§āϰāĻĻāĻžāĻšāĻāύāĻŋāϤ Autoimmune Disease-āĻāϰ āĻāĻŋāĻāĻŋā§āϏāĻžāĨ¤
7. Why prescribed: āϰā§āĻā§āϰ āĻāĻžāĻāϧā§āϰ āĻŦā§āϝāĻĨāĻž āĻāĻŦāĻ RA Factor test āĻĻā§āĻā§ āϏāĻŽā§āĻāĻžāĻŦā§āϝ inflammatory arthritis-āĻāϰ āĻāĻŋāĻāĻŋā§āϏāĻžāϰ āĻāĻĻā§āĻĻā§āĻļā§āϝ āĻ āύā§āĻŽāĻžāύ āĻāϰāĻž āϝāĻžāϝāĻŧāĨ¤ āĻāĻŋāύā§āϤ⧠āĻĒā§āϰā§āĻŦā§ āύāĻŋāĻļā§āĻāĻŋāϤ RA diagnosis āĻŦāĻž Methotrexate treatment history āĻĒāĻžāĻāϝāĻŧāĻž āϝāĻžāϝāĻŧāύāĻŋāĨ¤
8. Side Effects: Serious infection, herpes zoster, blood-count abnormalities, lipid elevation; āĻĒāĻžāĻļāĻžāĻĒāĻžāĻļāĻŋ Major Cardiovascular Events, Malignancy, Thrombosis āĻāĻŦāĻ mortality-related boxed warnings āĻā§āϰā§āϤā§āĻŦāĻĒā§āϰā§āĻŖāĨ¤
9. MedEx Link: Tofatin XR 11 mg â MedEx
10. Price & Composition: Unit ā§ŗ80; Strip ā§ŗ800āĨ¤ āĻāĻāĻ brand-āĻāϰ 5 mg immediate-release tablet āĻāĻā§āĨ¤
11. Mechanism: JAKâSTAT signaling pathway inhibit āĻāϰ⧠inflammatory cytokine signaling āĻāĻŽāĻžāϝāĻŧāĨ¤
12. Indications: āύāĻŋāϰā§āĻĻāĻŋāώā§āĻ āϰā§āĻā§āϰ āĻā§āώā§āϤā§āϰ⧠Rheumatoid Arthritis, Psoriatic Arthritis āĻāĻŦāĻ Ulcerative ColitisāĨ¤
13. Interactions & Contraindications: Strong CYP3A4 inhibitors, CYP3A4 inducers āĻāĻŦāĻ āĻ āύā§āϝāĻžāύā§āϝ immunosuppressive drugs āĻā§āϰā§āϤā§āĻŦāĻĒā§āϰā§āĻŖāĨ¤ Serious active infection-āĻ āĻāώā§āϧāĻāĻŋ āĻŦā§āϝāĻŦāĻšāĻžāϰ āĻāϰāĻž āĻāĻāĻŋāϤ āύāϝāĻŧāĨ¤
14. Precautions: CBC, LFT, renal function, lipid profile, TB screening, hepatitis screening, vaccination status āĻāĻŦāĻ infection assessment āĻā§āϰā§āϤā§āĻŦāĻĒā§āϰā§āĻŖāĨ¤ ā§Ŧā§Ģ āĻŦāĻāϰā§āϰ āĻŦā§āĻļāĻŋ āĻŦāϝāĻŧāϏ⧠āĻŦāĻŋāĻļā§āώ āϏāϤāϰā§āĻāϤāĻž āĻĒā§āϰāϝāĻŧā§āĻāύāĨ¤
15. Dosage: Prescription: 11 mg XR once at night for 20 daysāĨ¤ āĻāĻāĻŋ RA-āĻāϰ āĻāĻāĻāĻŋ āϏā§āĻŦā§āĻā§āϤ daily formulation, āĻāĻŋāύā§āϤ⧠dose appropriateness āϰā§āĻ, renal function, hepatic function āĻāĻŦāĻ treatment history-āĻāϰ āĻāĻĒāϰ āύāĻŋāϰā§āĻāϰāĻļā§āϞāĨ¤
16. Pregnancy & Lactation: Pregnancy-āϤ⧠fetal risk āĻāĻŦāĻ breastfeeding-āĻ safety concerns āϰāϝāĻŧā§āĻā§āĨ¤ āĻŦāϰā§āϤāĻŽāĻžāύ āϰā§āĻā§āϰ āĻā§āώā§āϤā§āϰ⧠āĻĒā§āϰāϝā§āĻā§āϝ āύāϝāĻŧāĨ¤
Clinical Verdict
Tofacitinib āϏāĻžāϧāĻžāϰāĻŖ āĻāĻžāĻāϧā§āϰ āĻŦā§āϝāĻĨāĻžāϰ āĻāώā§āϧ āύāϝāĻŧāĨ¤ āĻāĻāĻŋ āĻļā§āϰ⧠āĻāϰāĻžāϰ āĻāĻā§ inflammatory arthritis-āĻāϰ diagnosis āĻāĻŦāĻ āĻĒā§āϰā§āĻŦāĻŦāϰā§āϤ⧠treatment history āĻĒā§āϰāϤāĻŋāώā§āĻ āĻŋāϤ āĻĨāĻžāĻāĻž āĻĻāϰāĻāĻžāϰāĨ¤
āĻāĻ āϰā§āĻā§āϰ Common Cold āϞā§āĻāĻž āϰāϝāĻŧā§āĻā§āĨ¤ āϏāĻāĻā§āϰāĻŽāĻŖ āĻāϤāĻāĻž āĻā§āϰā§āϤāϰ, āĻāĻĻā§ active infection āĻāĻā§ āĻāĻŋ āύāĻž āĻāĻŦāĻ medication continuation āύāĻŋāϰāĻžāĻĒāĻĻ āĻāĻŋ āύāĻž prescribing physician-āĻā§ āĻĻā§āϰā§āϤ āϝāĻžāĻāĻžāĻ āĻāϰāϤ⧠āĻšāĻŦā§āĨ¤
EULAR-āĻāϰ 2025 RA management update, āϝāĻž 2026 āϏāĻžāϞ⧠āĻĒā§āϰāĻāĻžāĻļāĻŋāϤ āĻšāϝāĻŧā§āĻā§, JAK inhibitors āĻŦā§āϝāĻŦāĻšāĻžāϰā§āϰ āĻāĻā§ cardiovascular, malignancy āĻ thromboembolic risks āĻŦāĻŋāĻŦā§āĻāύāĻžāϰ āĻāĻĒāϰ āĻā§āϰā§āϤā§āĻŦ āĻĻāĻŋāϝāĻŧā§āĻā§āĨ¤
Confidence: 0.99 â Safety concerns; 0.34 â Evidence that this patient has RA.
7.6 Medicine No. 6 â Merolin 5 mg
Brand identification: āĻšāĻžāϤā§āϰ āϞā§āĻāĻž āĻĨā§āĻā§ Merolin 5 mg āϏāĻŦāĻā§āϝāĻŧā§ āϏāĻŽā§āĻāĻžāĻŦā§āϝ āĻĒāĻžāĻ āĨ¤ āĻāώā§āϧā§āϰ āĻĒā§āϝāĻžāĻā§āĻ āĻĻāĻŋāϝāĻŧā§ āύāĻŋāĻļā§āĻāĻŋāϤ āĻāϰāϤ⧠āĻšāĻŦā§āĨ¤
1. Generic: Mirogabalin Besylate.
2. Brand: Merolin 5 mg.
3. Alternate Brands: Migalin 5 mg, GabaFix 5 mg, Neumig 5 mg.
4. MedEx Therapeutic Class: Adjunct Anti-epileptic Drugs; Primary Anti-epileptic Drugs.
5. Pharmacological Class: Gabapentinoid; Îąâδ calcium-channel ligand.
6. Purpose: Neuropathic Pain āĻāĻŽāĻžāύā§āĨ¤
7. Why prescribed: Low Back Pain-āĻāϰ āϏāĻā§āĻā§ āϏāĻŽā§āĻāĻžāĻŦā§āϝ Neuropathic Component āϏāύā§āĻĻā§āĻš āĻāϰ⧠āĻĻā§āĻāϝāĻŧāĻž āĻšāϝāĻŧā§ āĻĨāĻžāĻāϤ⧠āĻĒāĻžāϰā§āĨ¤
8. Side Effects: Somnolence, dizziness, edema, weight gain āĻāĻŦāĻ impaired coordinationāĨ¤
9. MedEx Link: Merolin 5 mg â MedEx
10. Price & Composition: Unit ā§ŗ20; Strip ā§ŗ200āĨ¤ āĻāĻāĻ brand-āĻ 2.5 mg āĻ 10 mg āϰāϝāĻŧā§āĻā§āĨ¤
11. Mechanism: Voltage-Gated Calcium Channel-āĻāϰ Îąâδ subunit-āĻāϰ āϏāĻā§āĻā§ āϝā§āĻā§āϤ āĻšāϝāĻŧā§ neurotransmitter release āĻāĻŽāĻžāϝāĻŧāĨ¤
12. Indications: Peripheral Neuropathic Pain, Diabetic Peripheral Neuropathy āĻ Postherpetic NeuralgiaāĨ¤
13. Interactions & Contraindications: Sedatives, alcohol āĻ āĻ āύā§āϝāĻžāύā§āϝ CNS depressants-āĻāϰ āϏāĻā§āĻā§ sedation āĻŦāĻžāĻĄāĻŧāϤ⧠āĻĒāĻžāϰā§āĨ¤ Hypersensitivity-āϤ⧠contraindicatedāĨ¤
14. Precautions: āĻāĻŋāĻĄāύāĻŋāϰ āĻāĻžāϰā§āϝāĻāĻžāϰāĻŋāϤāĻž āĻ āύā§āϝāĻžāϝāĻŧā§ dose adjustment āĻĒā§āϰāϝāĻŧā§āĻāύāĨ¤ ā§Žā§Ģ āĻŦāĻāϰ āĻŦāϝāĻŧāϏ⧠Falls āĻāĻŦāĻ fracture risk āĻŦāĻŋāĻļā§āώāĻāĻžāĻŦā§ āĻŦāĻŋāĻŦā§āĻā§āϝāĨ¤
15. Dosage: Prescription: 5 mg twice daily for 15 daysāĨ¤ MedEx-āĻ āĻāĻāĻŋ āϏāĻžāϧāĻžāϰāĻŖ adult starting dose, āĻāĻŋāύā§āϤ⧠renal impairment āĻĨāĻžāĻāϞ⧠āĻāĻŽ dose āĻĻāϰāĻāĻžāϰ āĻšāϤ⧠āĻĒāĻžāϰā§āĨ¤
16. Pregnancy & Lactation: āĻĒāϰā§āϝāĻžāĻĒā§āϤ human safety evidence āϏā§āĻŽāĻŋāϤ; āĻĒā§āϰāϝāĻŧā§āĻāύ āĻ āύā§āϝāĻžāϝāĻŧā§ riskâbenefit assessmentāĨ¤ āĻŦāϰā§āϤāĻŽāĻžāύ āϰā§āĻā§āϰ āĻā§āώā§āϤā§āϰ⧠āĻĒā§āϰāϝā§āĻā§āϝ āύāϝāĻŧāĨ¤
Clinical Verdict: Neuropathic Pain-āĻāϰ āĻāĻŋāĻāĻŋā§āϏāĻžāϝāĻŧ āĻŦā§āϝāĻŦāĻšāĻžāϰ āĻāĻĒāϝā§āĻā§āϤ āĻšāϤ⧠āĻĒāĻžāϰā§; āĻāĻŋāύā§āϤ⧠āĻĒā§āϰā§āϏāĻā§āϰāĻŋāĻĒāĻļāύ⧠Burning Pain, Tingling, Numbness āĻŦāĻž Radiculopathy āϞā§āĻāĻž āύā§āĻāĨ¤
Confidence: 0.83 â Brand identification; 0.43 â Neuropathic indication in this patient.
7.7 Medicine No. 7 â Zo-MUPS 40 mg
1. Generic: Esomeprazole.
2. Brand: Zo-MUPS 40 mg.
3. Alternate Brands: Emep MUPS 40 mg, Sergel MUPS 40 mg.
4. MedEx Therapeutic Class: Proton Pump Inhibitor.
5. Pharmacological Class: PPI.
6. Purpose: Gastric acid suppression.
7. Why prescribed: Sulindac-related upper GI injury risk āĻāĻŽāĻžāύā§āϰ āĻāĻĻā§āĻĻā§āĻļā§āϝ⧠āĻ āĻĨāĻŦāĻž acid-related symptoms-āĻāϰ āĻāύā§āϝāĨ¤
8. Side Effects: Headache, diarrhea, abdominal discomfort; āĻĻā§āϰā§āĻāĻŽā§āϝāĻŧāĻžāĻĻā§ āύāĻŋāϰā§āĻĻāĻŋāώā§āĻ āϰā§āĻā§āϰ āĻā§āώā§āϤā§āϰ⧠hypomagnesemia, fracture āĻāĻŦāĻ kidney-related complications āĻŦāĻŋāĻŦā§āĻā§āϝāĨ¤
9. MedEx Link: Zo-MUPS 40 mg â MedEx
10. Price & Composition: Unit ā§ŗ17; Strip ā§ŗ170āĨ¤ āĻāĻāĻ brand-āĻ 20 mg āϰāϝāĻŧā§āĻā§āĨ¤
11. Mechanism: Gastric Hâē/Kâē-ATPase proton pump inhibit āĻāϰ⧠acid secretion āĻāĻŽāĻžāϝāĻŧāĨ¤
12. Indications: GERD, erosive esophagitis, peptic ulcer āĻāĻŦāĻ NSAID-associated ulcer prevention/treatmentāĨ¤
13. Interactions & Contraindications: CYP2C19-related interactions āĻāĻŦāĻ pH-dependent absorption of some drugs āĻā§āϰā§āϤā§āĻŦāĻĒā§āϰā§āĻŖāĨ¤ Hypersensitivity-āϤ⧠contraindicatedāĨ¤
14. Precautions: āĻĻā§āϰā§āĻāĻŽā§āϝāĻŧāĻžāĻĻāĻŋ āĻ āĻĒā§āϰāϝāĻŧā§āĻāύā§āϝāĻŧ PPI āĻŦā§āϝāĻŦāĻšāĻžāϰ āĻāĻĄāĻŧāĻžāϤ⧠āĻšāĻŦā§āĨ¤ GI protection āĻĨāĻžāĻāϞā§āĻ NSAID-induced bleeding risk āĻĒā§āϰā§āĻĒā§āϰāĻŋ āĻĻā§āϰ āĻšāϝāĻŧ āύāĻžāĨ¤
15. Dosage: Prescription: 40 mg twice daily, āĻāĻžāĻŦāĻžāϰā§āϰ ā§Šā§Ļ āĻŽāĻŋāύāĻŋāĻ āĻāĻā§, ā§§ā§Ģ āĻĻāĻŋāύāĨ¤ MedEx-āĻ āĻ āϧāĻŋāĻāĻžāĻāĻļ āϏāĻžāϧāĻžāϰāĻŖ GERD/NSAID-protection indication-āĻāϰ āĻāύā§āϝ once-daily regimen āϰāϝāĻŧā§āĻā§; āϤāĻžāĻ twice-daily 40 mg-āĻāϰ indication āϝāĻžāĻāĻžāĻ āĻāϰāĻž āĻāĻāĻŋāϤāĨ¤
16. Pregnancy & Lactation: Pregnancy/breastfeeding-āĻ āĻŦā§āϝāĻŦāĻšāĻžāϰ āĻāĻŋāĻāĻŋā§āϏāĻā§āϰ riskâbenefit assessment āĻ āύā§āϝāĻžāϝāĻŧā§āĨ¤
Clinical Verdict: Gastric protection-āĻāϰ āϏāĻŽā§āĻāĻžāĻŦā§āϝ āĻāĻĻā§āĻĻā§āĻļā§āϝ āϝā§āĻā§āϤāĻŋāϏāĻāĻāϤ; āĻāĻŋāύā§āϤ⧠80 mg/day āĻāĻ āϰā§āĻā§āϰ āĻā§āώā§āϤā§āϰ⧠āĻā§āύ āĻĒā§āϰāϝāĻŧā§āĻāύ, āϤāĻž āύāĻĨāĻŋāĻā§āĻā§āϤ āύā§āĻāĨ¤
Confidence: 0.99 â Drug identification; 0.79 â Presumed purpose.
7.8 Medicine No. 8 â Gavirad Suspension
1. Generic: Sodium Alginate + Sodium Bicarbonate + Calcium Carbonate.
2. Brand: Gavirad.
3. Alternate Brands: Gavinil, Gavinor, Gaviplus â āĻāĻāĻ composition āĻ strength āϝāĻžāĻāĻžāĻ āϏāĻžāĻĒā§āĻā§āώā§āĨ¤
4. MedEx Therapeutic Class: Antacids.
5. Pharmacological Class: Alginate-based reflux suppressant and antacid combination.
6. Purpose: Acid Reflux āĻ Heartburn-āĻāϰ symptomatic reliefāĨ¤
7. Why prescribed: Gastric discomfort-āĻāϰ āĻāĻŋāĻāĻŋā§āϏāĻž āĻ āĻĨāĻŦāĻž NSAID-associated upper GI symptoms āĻāĻŽāĻžāύā§āϰ āĻāĻĻā§āĻĻā§āĻļā§āϝ⧠āĻšāϤ⧠āĻĒāĻžāϰā§āĨ¤
8. Side Effects: Constipation, belching, bloating āĻāĻŦāĻ abdominal discomfortāĨ¤
9. MedEx Link: Gavirad â MedEx
10. Price & Composition: 200 mL bottle ā§ŗ300; 10 mL sachet ā§ŗ15āĨ¤ āĻĒā§āϰāϤāĻŋ 10 mL-āĻ Sodium Alginate 500 mg + Sodium Bicarbonate 267 mg + Calcium Carbonate 160 mgāĨ¤
11. Mechanism: Gastric contents-āĻāϰ āĻāĻĒāϰ protective alginate raft āϤā§āϰāĻŋ āĻāϰ⧠āĻāĻŦāĻ stomach acid neutralize āĻāϰā§āĨ¤
12. Indications: GERD, Heartburn, IndigestionāĨ¤
13. Interactions & Contraindications: āĻ āύā§āϝ āĻāĻŋāĻā§ oral medicines-āĻāϰ absorption āĻāĻŽāϤ⧠āĻĒāĻžāϰā§; MedEx āĻ āύā§āϝāĻžāϝāĻŧā§ āύāĻŋāϰā§āĻĻāĻŋāώā§āĻ āĻāώā§āϧ āĻĨā§āĻā§ āĻĒā§āϰāĻžāϝāĻŧ āĻĻā§āĻ āĻāĻŖā§āĻāĻž āĻŦā§āϝāĻŦāϧāĻžāύ āĻĒā§āϰāϝāĻŧā§āĻāύ āĻšāϤ⧠āĻĒāĻžāϰā§āĨ¤ Hypersensitivity-āϤ⧠contraindicatedāĨ¤
14. Precautions: Heart Failure, severe renal disease āĻ āĻĨāĻŦāĻž sodium-restricted diet āĻĨāĻžāĻāϞ⧠sodium/calcium content āĻŦāĻŋāĻŦā§āĻāύāĻž āĻāϰāϤ⧠āĻšāĻŦā§āĨ¤
15. Dosage: Prescription: 2 teaspoons three times daily for 15 daysāĨ¤ āĻāĻāĻāĻŋ standard 5 mL measuring spoon āϧāϰ⧠āĻĒā§āϰāϤāĻŋ dose 10 mLāĨ¤ MedEx adult dosage: 10â20 mL after meals and at bedtime, up to four times dailyāĨ¤
16. Pregnancy & Lactation: MedEx āĻ āύā§āϝāĻžāϝāĻŧā§ clinically necessary āĻšāϞ⧠āĻŦā§āϝāĻŦāĻšāĻžāϰ āĻāϰāĻž āϝāĻžāϝāĻŧ; āĻŦāϰā§āϤāĻŽāĻžāύ āϰā§āĻā§āϰ āĻā§āώā§āϤā§āϰ⧠āĻĒā§āϰāϝā§āĻā§āϝ āύāϝāĻŧāĨ¤
Clinical Verdict: Acid reflux-āĻāϰ symptomatic treatment-āĻāϰ āϏāĻā§āĻā§ āϏāĻžāĻŽāĻā§āĻāϏā§āϝāĻĒā§āϰā§āĻŖ; āϤāĻŦā§ āĻŽā§āϞ C/C-āϤ⧠Heartburn āĻŦāĻž Dyspepsia āϞā§āĻāĻž āύā§āĻāĨ¤
Confidence: 0.90 â Brand identification; 0.69 â Patient-specific indication.
7.9 Medicine No. 9 â Brofex TS
â ī¸ Important Dose Discrepancy
1. Generic: Dextromethorphan Polistirex.
2. Brand: Brofex TS.
3. Alternate Brands: MedEx-āĻ āĻāĻāĻ Extended-Release Polistirex formulation-āĻāϰ āĻ āύā§āϝ brand āύāĻŋāĻļā§āĻāĻŋāϤ āĻāϰāĻž āϝāĻžāϝāĻŧāύāĻŋāĨ¤ Immediate-release Dextromethorphan products āϏāϰāĻžāϏāϰāĻŋ interchangeable āύāϝāĻŧāĨ¤
4. MedEx Therapeutic Class: Cough Suppressant.
5. Pharmacological Class: Centrally acting non-opioid antitussive.
6. Purpose: Dry Cough suppression.
7. Why prescribed: Common Cold-āĻāϰ āϏāĻā§āĻā§ dry cough āϰāϝāĻŧā§āĻā§ āĻŦāϞ⧠āĻ āύā§āĻŽāĻžāύ āĻāϰāĻž āϝāĻžāϝāĻŧ, āϝāĻĻāĻŋāĻ C/C-āϤ⧠cough āĻāϞāĻžāĻĻāĻžāĻāĻžāĻŦā§ āϞā§āĻāĻž āύā§āĻāĨ¤
8. Side Effects: Dizziness, nausea, confusion; overdose-āĻ agitation, altered consciousness āĻāĻŦāĻ respiratory depression āĻšāϤ⧠āĻĒāĻžāϰā§āĨ¤
9. MedEx Link: Brofex TS â MedEx
10. Price & Composition: 100 mL bottle ā§ŗ100āĨ¤ Strength: Dextromethorphan equivalent 30 mg/5 mLāĨ¤
11. Mechanism: Medullary cough centre-āĻāϰ āĻāĻĒāϰ āĻāĻžāĻ āĻāϰ⧠cough reflex āĻāĻŽāĻžāϝāĻŧāĨ¤
12. Indications: Acute or chronic dry/unproductive coughāĨ¤
13. Interactions & Contraindications: MAO inhibitors-āĻāϰ āϏāĻā§āĻā§ contraindicated; āĻ āύā§āϝāĻžāύā§āϝ serotonergic medicines-āĻāϰ āϏāĻā§āĻā§ serotonin toxicity-āĻāϰ āĻā§āĻāĻāĻŋ āĻŦāĻŋāĻŦā§āĻā§āϝāĨ¤
14. Precautions: Elderly patients, liver impairment āĻāĻŦāĻ neurological symptoms āĻĨāĻžāĻāϞ⧠āϏāϤāϰā§āĻāϤāĻžāĨ¤
15. Dosage: Prescription: 2 teaspoons à 3 times daily for 15 daysāĨ¤
āϝāĻĻāĻŋ āĻĒā§āϰāϤāĻŋ āĻāĻžāĻŽāĻ 5 mL āĻšāϝāĻŧ:
10 mL Ã 3 = 30 mL/day = 180 mg/dayāĨ¤
āĻāĻŋāύā§āϤ⧠MedEx-āĻāϰ Brofex TS Extended-Release Suspension adult dose:
10 mL every 12 hours; maximum 20 mL/24 hours = 120 mg/dayāĨ¤
āĻ āϰā§āĻĨāĻžā§ āĻĒā§āϰā§āϏāĻā§āϰāĻŋāĻĒāĻļāύā§āϰ āϞāĻŋāĻāĻŋāϤ regimen MedEx maximum-āĻāϰ 1.5 āĻā§āĻŖāĨ¤
16. Pregnancy & Lactation: Pregnancy āĻ breastfeeding-āĻ āĻŦā§āϝāĻŦāĻšāĻžāϰā§āϰ āϤāĻĨā§āϝ āϏā§āĻŽāĻŋāϤ; āϰā§āĻā§āϰ āĻā§āώā§āϤā§āϰ⧠āĻĒā§āϰāϝā§āĻā§āϝ āύāϝāĻŧāĨ¤
Clinical Verdict
āĻāĻ āĻĄā§āĻ prescribing doctor āĻŦāĻž pharmacist āĻĻāĻŋāϝāĻŧā§ āĻĒāϰāĻŦāϰā§āϤ⧠dose-āĻāϰ āĻāĻā§āĻ āϝāĻžāĻāĻžāĻ āĻāϰāĻž āĻĒā§āϰāϝāĻŧā§āĻāύāĨ¤ āĻāĻāĻŋ transcription error, spoon-size misunderstanding āĻ āĻĨāĻŦāĻž prescribing error āĻāĻŋ āύāĻž āύāĻŋāĻļā§āĻāĻŋāϤ āĻāϰāϤ⧠āĻšāĻŦā§āĨ¤
Confidence: 0.99 â MedEx maximum dose; 0.96 â Dose discrepancy, assuming 5 mL teaspoons.
7.10 Medicine No. 10 â Voligel Max 2%
1. Generic: Diclofenac Sodium.
2. Brand: Voligel Max 2% w/w.
3. Alternate Brands: Voltagel DS 2% āĻāĻŦāĻ āĻ āύā§āϝāĻžāύā§āϝ equivalent-strength topical diclofenac formulationsāĨ¤
4. MedEx Therapeutic Class: Drugs for Osteoarthritis; Drugs used for Rheumatoid Arthritis; NSAIDs.
5. Pharmacological Class: Topical NSAID.
6. Purpose: Local pain and inflammation reliefāĨ¤
7. Why prescribed: Bilateral Shoulder Pain āĻāĻŦāĻ Low Back PaināĨ¤
8. Side Effects: Local skin irritation, redness, rash; systemic adverse effects āϤā§āϞāύāĻžāĻŽā§āϞāĻ āĻāĻŽ āĻšāϞā§āĻ āĻ āϏāĻŽā§āĻāĻŦ āύāϝāĻŧāĨ¤
9. MedEx Link: Voligel Max 2% â MedEx
10. Price & Composition: 50 g tube ā§ŗ170āĨ¤ āĻāĻāĻ brand-āĻāϰ 1% topical gel āϰāϝāĻŧā§āĻā§āĨ¤
11. Mechanism: Cyclooxygenase-mediated prostaglandin synthesis āĻāĻŽāĻžāϝāĻŧāĨ¤
12. Indications: Musculoskeletal pain, osteoarthritis-related pain āĻāĻŦāĻ local inflammatory conditionsāĨ¤
13. Interactions & Contraindications: NSAID hypersensitivity; oral NSAID-āĻāϰ āϏāĻā§āĻā§ combined exposure āĻāĻŦāĻ anticoagulant use-āĻāϰ āĻā§āώā§āϤā§āϰ⧠āϏāϤāϰā§āĻāϤāĻžāĨ¤
14. Precautions: Open wound, eyes āĻŦāĻž mucous membranes-āĻ āĻŦā§āϝāĻŦāĻšāĻžāϰ āύāϝāĻŧāĨ¤ āĻŦāĻĄāĻŧ āĻ āĻāĻļā§ āĻ āϤāĻŋāϰāĻŋāĻā§āϤ āĻŦā§āϝāĻŦāĻšāĻžāϰ āĻāĻĄāĻŧāĻžāϤ⧠āĻšāĻŦā§āĨ¤
15. Dosage: Doctor āϞāĻŋāĻā§āĻā§āύ āĻŦā§āϝāĻĨāĻžāϰ āϏā§āĻĨāĻžāύ⧠āĻĻāĻŋāύ⧠āĻĻā§āĻāĻŦāĻžāϰ āϞāĻžāĻāĻžāϤā§, āĻŽā§āϝāĻžāϏāĻžāĻ āύāĻž āĻāϰāϤā§āĨ¤ MedEx-āĻāϰ general diclofenac gel information formulation āĻ āύā§āϝāĻžāϝāĻŧā§ āĻāĻŋāύā§āύ āĻšāϤ⧠āĻĒāĻžāϰā§; prescribed frequency āύāĻŋāĻļā§āĻāĻŋāϤ āĻāϰāϤ⧠āĻšāĻŦā§āĨ¤
16. Pregnancy & Lactation: Pregnancy-āϤ⧠āĻŦāĻŋāĻļā§āώ āϏāϤāϰā§āĻāϤāĻž; āĻŦāϰā§āϤāĻŽāĻžāύ āϰā§āĻā§āϰ āĻā§āώā§āϤā§āϰ⧠āĻĒā§āϰāϝā§āĻā§āϝ āύāϝāĻŧāĨ¤
Clinical Verdict: Localized musculoskeletal pain-āĻāϰ āĻāύā§āϝ āĻāĻĒāϝā§āĻā§āϤ āĻšāϤ⧠āĻĒāĻžāϰā§āĨ¤ Oral Sulindac-āĻāϰ āϏāĻā§āĻā§ systemic NSAID risk āĻĒāϰā§āϝāĻžāϞā§āĻāύāĻž āĻāϰāĻž āĻāĻāĻŋāϤāĨ¤
Confidence: 0.99 â Drug identification; 0.90 â Intended indication.
8. đ¨ My Clinical Working Assessment â Evidence-Based
Provisional Working Diagnosis
Symptomatic Nocturia of Undetermined Etiology, with Suspected Urinary Storage Dysfunction; Rule Out Symptomatic Lower UTI. Associated Bilateral Shoulder Pain and Low Back Pain of Undetermined Etiology; Evaluate for Degenerative and Inflammatory Musculoskeletal Disease.
āĻŦāĻžāĻāϞāĻž
āĻāĻžāϰāĻŖ āĻāĻāύ⧠āύāĻŋāϰā§āϧāĻžāϰāĻŋāϤ āύāϝāĻŧ āĻāĻŽāύ āϰāĻžāϤā§āϰ āĻĒā§āϰāϏā§āϰāĻžāĻŦā§āϰ āϏāĻŽāϏā§āϝāĻž; āϏāĻŽā§āĻāĻžāĻŦā§āϝ āĻŽā§āϤā§āϰāĻĨāϞāĻŋāϰ āĻĒā§āϰāϏā§āϰāĻžāĻŦ āϧāϰ⧠āϰāĻžāĻāĻžāϰ āĻāĻžāϰā§āϝāĻāĻžāϰāĻŋāϤāĻžāĻāύāĻŋāϤ āϏāĻŽāϏā§āϝāĻžāĨ¤ āĻŽā§āϤā§āϰāύāĻžāϞā§āϰ āϏāĻāĻā§āϰāĻŽāĻŖ āĻāĻā§ āĻāĻŋ āύāĻž āĻĒāϰā§āĻā§āώāĻž āĻāϰ⧠āĻĻā§āĻāϤ⧠āĻšāĻŦā§āĨ¤ āĻĒāĻžāĻļāĻžāĻĒāĻžāĻļāĻŋ āĻāĻāϝāĻŧ āĻāĻžāĻāϧ āĻ āĻā§āĻŽāϰ⧠āĻŦā§āϝāĻĨāĻž, āϝāĻžāϰ āĻāĻžāϰāĻŖ āĻāĻāύ⧠āύāĻŋāĻļā§āĻāĻŋāϤ āύāϝāĻŧāĨ¤ āĻā§āώāϝāĻŧāĻāύāĻŋāϤ āĻ āĻĒā§āϰāĻĻāĻžāĻšāĻāύāĻŋāϤ āĻŦāĻžāϤāϰā§āĻ āĻŽā§āϞā§āϝāĻžāϝāĻŧāύ āĻāϰāĻž āĻĒā§āϰāϝāĻŧā§āĻāύāĨ¤
Confidence: 0.89 â Accuracy of the problem-based working assessment, not confirmation of a specific disease.
Differential Diagnosis
| Diagnosis | Clinical Support | Missing Evidence | Confidence |
|---|---|---|---|
| Nocturia â cause undetermined | Explicit C/C | Frequency, volume, diary | 0.99 |
| Possible OAB | Nocturia; Mirabegron prescribed | Urgency and exclusion of other causes | 0.56 |
| Possible Symptomatic Lower UTI | Nitrofurantoin prescribed | Localizing symptoms, urine findings | 0.43 |
| Degenerative Musculoskeletal Pain | Advanced age, shoulder/LBP | Joint and spine examination | 0.61 |
| Rheumatoid Arthritis | Tofacitinib and RF test | Synovitis, RF/Anti-CCP, history | 0.25 |
| Polymyalgia Rheumatica | Age 85; bilateral shoulder pain | Morning stiffness, ESR/CRP, examination | 0.35 |
| Neuropathic Pain | Mirogabalin prescribed | Neuropathic pain features | 0.32 |
| Viral URTI | Common Cold documented | Respiratory history/examination | 0.76 |
Confidence scores are qualitative evidence-support estimates, not validated statistical probabilities.
Clinical reasoning
Most defensible conclusion: Nocturia āĻāĻŦāĻ musculoskeletal pain āύāĻŋāĻļā§āĻāĻŋāϤāĻāĻžāĻŦā§ āύāĻĨāĻŋāĻā§āĻā§āϤāĨ¤ āĻāĻŋāύā§āϤ⧠OAB, UTI āĻŦāĻž RAâāĻā§āύā§āĻāĻŋāĻ āύāĻŋāĻļā§āĻāĻŋāϤ āĻāϰāĻžāϰ āĻŽāϤ⧠āϝāĻĨā§āώā§āĻ āϤāĻĨā§āϝ āύā§āĻāĨ¤
Most important missing detail: āϰā§āĻā§āϰ āĻĒā§āϰā§āĻŦā§ Rheumatoid Arthritis diagnosed āĻāĻŋāϞ āĻāĻŋ āύāĻž āĻāĻŦāĻ Tofacitinib āĻāĻā§ āĻĨā§āĻā§āĻ āĻāϞāĻāĻŋāϞ āĻāĻŋ āύāĻžāĨ¤ āĻāĻ āϤāĻĨā§āϝ medication safety āĻ diagnosis āĻĻā§āĻāĻŋāĻ āĻāϞā§āϞā§āĻāϝā§āĻā§āϝāĻāĻžāĻŦā§ āĻĒāϰāĻŋāĻŦāϰā§āϤāύ āĻāϰāϤ⧠āĻĒāĻžāϰā§āĨ¤
Confidence: 0.96
9. đ¨ Final Diagnostic Interpretation and DoctorâReviewer Comparison
đ§ A. Doctor’s Explicit Diagnosis
Doctor’s Dx: Not documented in the prescription.
āĻ āϰā§āĻĨāĻžā§ āĻĄāĻžāĻā§āϤāĻžāϰ āϰā§āĻāύāĻŋāϰā§āĻŖāϝāĻŧā§āϰ āĻā§āύ⧠āύāĻŋāϰā§āĻĻāĻŋāώā§āĻ āύāĻžāĻŽ āϞā§āĻā§āύāύāĻŋāĨ¤
āϤāĻŦā§ āĻāĻŋāĻāĻŋā§āϏāĻžāϰ āϧāϰāύ āĻĻā§āĻā§ āύāĻŋāĻā§āϰ treatment targets āĻ āύā§āĻŽāĻžāύ āĻāϰāĻž āϝāĻžāϝāĻŧ:
- Urinary infection or urinary symptoms
- Bladder overactivity/spasm
- Musculoskeletal or inflammatory pain
- Possible autoimmune inflammatory disease
- Gastric acid-related symptoms or prevention
- Dry cough associated with common cold
āĻāĻā§āϞ⧠āĻĄāĻžāĻā§āϤāĻžāϰā§āϰ āϞāĻŋāĻāĻŋāϤ Diagnosis āύāϝāĻŧāĨ¤
Confidence: 0.99 â No explicit diagnosis; 0.70 â Inferred treatment targets.
đŠ B. My Clinical Working Diagnosis
Nocturia with possible urinary storage dysfunction; UTI to be excluded; bilateral shoulder and lumbar pain with undetermined cause; inflammatory arthritis requires separate evaluation.
Confidence: 0.87 â Appropriate provisional formulation.
đ§ C. Doctor’s Dx vs My Dx â Comparison
| Parameter | Doctor’s Prescription | My Assessment | Agreement |
|---|---|---|---|
| Nocturia | Explicit complaint | Confirmed symptom | đŠ Yes |
| UTI | Nitrofurantoin prescribed | Possible, unconfirmed | đ§ Partial |
| OAB | Mirabegron prescribed | Possible, not established | đ§ Partial |
| Shoulder Pain | Explicit complaint | Confirmed symptom | đŠ Yes |
| Rheumatoid Arthritis | Tofacitinib prescribed; RF ordered | Cannot confirm RA | đ§ Uncertain |
| Neuropathic Pain | Mirogabalin likely prescribed | Neuropathy not documented | đ§ Uncertain |
| Common Cold | Explicit complaint | Probable uncomplicated URTI | đŠ Broadly consistent |
| Gastric Disease | Acid-suppressive treatment | No documented GI symptoms | đ§ Uncertain |
đŠ Similarities â āĻŽāĻŋāϞ
1. Urinary symptoms āĻāĻŋāĻāĻŋā§āϏāĻžāϰ āĻāĻāĻāĻŋ āĻĒā§āϰāϧāĻžāύ āϞāĻā§āώā§āϝâāĻāϤ⧠āĻļāĻā§āϤāĻŋāĻļāĻžāϞ⧠āĻŽāĻŋāϞ āϰāϝāĻŧā§āĻā§āĨ¤
2. Shoulder āĻāĻŦāĻ lower-back pain-āĻāϰ āĻāĻŋāĻāĻŋā§āϏāĻž āĻĻā§āĻāϝāĻŧāĻž āĻšāϝāĻŧā§āĻā§âāĻāĻāĻŋāĻ āĻāĻĒāϏāϰā§āĻā§āϰ āϏāĻā§āĻā§ āϏāĻžāĻŽāĻā§āĻāϏā§āϝāĻĒā§āϰā§āĻŖāĨ¤
3. Common Cold-āĻāϰ symptomatic management-āĻāϰ āĻā§āώā§āĻāĻž āĻāϰāĻž āĻšāϝāĻŧā§āĻā§āĨ¤
Confidence: 0.94
đ§ Dissimilarities / Uncertainties â āĻ āĻŽāĻŋāϞ
1. UTI-āϰ āĻāύā§āϝ antibiotic āĻĻā§āĻāϝāĻŧāĻž āĻšāϞā§āĻ āϏāĻāĻā§āϰāĻŽāĻŖ āύāĻŋāĻļā§āĻāĻŋāϤ āĻāϰāĻžāϰ āĻĒā§āϰāĻŽāĻžāĻŖ āύā§āĻāĨ¤
2. Tofacitinib āĻāĻāĻāĻŋ āĻļāĻā§āϤāĻŋāĻļāĻžāϞ⧠immunomodulating drug; āĻļā§āϧ⧠shoulder pain āĻ āĻĨāĻŦāĻž pending RA Factor-āĻāϰ āĻāĻŋāϤā§āϤāĻŋāϤ⧠āĻāϰ indication āĻĒā§āϰāϤāĻŋāώā§āĻ āĻŋāϤ āĻšāϝāĻŧ āύāĻžāĨ¤
3. Gabapentinoid āĻĻā§āĻāϝāĻŧāĻž āĻšāϞā§āĻ Neuropathic Pain-āĻāϰ characteristic features āύāĻĨāĻŋāĻā§āĻā§āϤ āύā§āĻāĨ¤
4. Acid-suppressive treatment āĻĨāĻžāĻāϞā§āĻ GERD āĻŦāĻž Ulcer-āĻāϰ diagnosis āϞā§āĻāĻž āύā§āĻāĨ¤
Confidence: 0.97
Diagnostic Conclusion
Doctor’s explicit Dx āĻāĻŦāĻ My Dx-āĻāϰ āϏāϰāĻžāϏāϰāĻŋ similarity percentage āύāĻŋāϰā§āĻŖāϝāĻŧ āĻāϰāĻž āϏāĻŽā§āĻāĻŦ āύāϝāĻŧ, āĻāĻžāϰāĻŖ Doctor’s Dx āϞā§āĻāĻž āύā§āĻāĨ¤
āϤāĻŦā§ prescribed medicines-āĻāϰ apparent therapeutic goals āĻāĻŦāĻ working assessment-āĻāϰ āĻŽāϧā§āϝ⧠āĻāĻāĻļāĻŋāĻ āĻŽāĻŋāϞ āϰāϝāĻŧā§āĻā§āĨ¤
Confidence: 0.99
10. Guideline-Based Management and Treatment Review
āĻāĻ āϰā§āĻā§āϰ āĻā§āώā§āϤā§āϰ⧠āύāϤā§āύ āĻāώā§āϧ āϝā§āĻ āĻāϰāĻžāϰ āĻāĻā§ āĻŦāĻŋāĻĻā§āϝāĻŽāĻžāύ āĻāĻŋāĻāĻŋā§āϏāĻžāϰ āύāĻŋāϰāĻžāĻĒāϤā§āϤāĻž āĻāĻŦāĻ diagnosis āύāĻŋāĻļā§āĻāĻŋāϤ āĻāϰāĻž āĻŦā§āĻļāĻŋ āĻā§āϰā§āϤā§āĻŦāĻĒā§āϰā§āĻŖāĨ¤
A. Nocturia / Possible OAB
AUA/SUFU 2024 āĻ āύā§āϝāĻžāϝāĻŧā§ āĻĒā§āϰāĻĨāĻŽā§ History, Physical Examination, Urinalysis, Bladder Diary āĻ āĻĒā§āϰāϝāĻŧā§āĻāύ āĻ āύā§āϝāĻžāϝāĻŧā§ PVR assessment āĻāϰāĻž āĻāĻāĻŋāϤāĨ¤
āϝāĻĻāĻŋ OAB āύāĻŋāĻļā§āĻāĻŋāϤ āĻšāϝāĻŧ, āϤāĻāύ Bladder Training, Behavioral Measures āĻāĻŦāĻ āĻĒā§āϰāϝāĻŧā§āĻāύāĻŽāϤ⧠Pharmacotherapy āĻŦāĻŋāĻŦā§āĻāύāĻž āĻāϰāĻž āϝāĻžāϝāĻŧāĨ¤
Confidence: 0.98
B. Possible UTI
UTI-āϏāĻāĻļā§āϞāĻŋāώā§āĻ āĻāĻĒāϏāϰā§āĻ āĻĨāĻžāĻāϞ⧠appropriate urine testing āĻ āĻĒā§āϰāϝāĻŧā§āĻāύāĻŽāϤ⧠culture āĻāϰāϤ⧠āĻšāĻŦā§āĨ¤
āĻŦāϝāĻŧāϏā§āĻ āϰā§āĻā§āϰ āĻļā§āϧ⧠Nocturia āĻŦāĻž incidental bacteriuria āĻĻā§āĻā§ antibiotic āĻāĻŋāĻāĻŋā§āϏāĻžāϰ āϏāĻŋāĻĻā§āϧāĻžāύā§āϤ āύā§āĻāϝāĻŧāĻž āĻāĻāĻŋāϤ āύāϝāĻŧāĨ¤
Nitrofurantoin āĻŦā§āϝāĻŦāĻšāĻžāϰā§āϰ āĻāĻā§ renal function āϝāĻžāĻāĻžāĻ āĻāϰā§āϰāĻŋāĨ¤ NICE guidance āĻ āύā§āϝāĻžāϝāĻŧā§ eGFR 45 mL/min/1.73m²-āĻāϰ āύāĻŋāĻā§ āϏāĻžāϧāĻžāϰāĻŖāϤ āĻŦā§āϝāĻŦāĻšāĻžāϰ āĻ āύā§āĻĒāϝā§āĻā§āϤ; eGFR 30â44 āĻšāϞ⧠āύāĻŋāϰā§āĻĻāĻŋāώā§āĻ āĻĒāϰāĻŋāϏā§āĻĨāĻŋāϤāĻŋāϤ⧠āϏāϤāϰā§āĻāϤāĻžāϰ āϏāĻā§āĻā§ āϏā§āĻŦāϞā§āĻĒāĻŽā§āϝāĻŧāĻžāĻĻāĻŋ āĻŦā§āϝāĻŦāĻšāĻžāϰ āĻŦāĻŋāĻŦā§āĻāĻŋāϤ āĻšāϤ⧠āĻĒāĻžāϰā§āĨ¤
Confidence: 0.99
C. Possible Inflammatory Arthritis
Clinical joint examination, inflammatory markers, RA serology āĻāĻŦāĻ āĻĒā§āϰā§āĻŦā§āϰ diagnosis/treatment history āϝāĻžāĻāĻžāĻ āĻāϰāϤ⧠āĻšāĻŦā§āĨ¤
Confirmed RA āĻĨāĻžāĻāϞ⧠disease activity, treatment response āĻāĻŦāĻ comorbidities āĻ āύā§āϝāĻžāϝāĻŧā§ DMARD āύāĻŋāϰā§āĻŦāĻžāĻāύ āĻāϰāĻž āĻšāϝāĻŧāĨ¤
Tofacitinib āĻļā§āϰ⧠āĻŦāĻž āĻāĻžāϞāĻŋāϝāĻŧā§ āϝāĻžāĻāϝāĻŧāĻžāϰ āϏāĻŋāĻĻā§āϧāĻžāύā§āϤ Rheumatologist-āĻāϰ āϏāĻā§āĻā§ āϝāĻžāĻāĻžāĻ āĻāϰāĻž āĻŦāĻŋāĻļā§āώāĻāĻžāĻŦā§ āĻā§āϰā§āϤā§āĻŦāĻĒā§āϰā§āĻŖāĨ¤
Confidence: 0.98
D. Musculoskeletal Pain
Degenerative, inflammatory āĻ neuropathic pain āĻāϞāĻžāĻĻāĻž āĻāϰāϤ⧠āĻšāĻŦā§āĨ¤
Pain treatment āύāĻŋāϰā§āĻŦāĻžāĻāύ āĻāϰāϤ⧠Kidney Function, GI Bleeding Risk, Falls Risk āĻāĻŦāĻ Polypharmacy āĻŦāĻŋāĻŦā§āĻāύāĻž āĻāϰāϤ⧠āĻšāĻŦā§āĨ¤
Confidence: 0.97
11. Bangladesh Prescription Practice â MedEx-Based Drug Options
Table 2: Disease-Specific Medicines Used in Bangladesh
āύāĻŋāĻā§āϰ āϤāĻžāϞāĻŋāĻāĻžāĻāĻŋ āϰā§āĻāĻāĻŋāϤā§āϤāĻŋāĻ āĻĒā§āϰāĻāϞāĻŋāϤ therapeutic options-āĻāϰ āĻāĻĻāĻžāĻšāϰāĻŖāĨ¤ āĻāĻāĻ āϰā§āĻā§āϰ āĻāύā§āϝ āϏāĻŦāĻā§āϞ⧠āĻāĻāϏāĻā§āĻā§ āĻŦā§āϝāĻŦāĻšāĻžāϰāϝā§āĻā§āϝ āύāϝāĻŧ āĻāĻŦāĻ āĻāĻāĻŋ āύāϤā§āύ Prescription āύāϝāĻŧāĨ¤
| Clinical Condition | Generic Medicine | Example Bangladesh Brand | Purpose |
|---|---|---|---|
| Confirmed susceptible Lower UTI | Nitrofurantoin | Nintoin SR | Urinary antibacterial |
| Confirmed susceptible Lower UTI | Fosfomycin | Brand/strength must be verified | Urinary antibacterial |
| OAB | Mirabegron | M-Beg, Betmira ER | Reduce urgency/frequency |
| Bladder Spasm | Flavoxate | Uroza, Urilax | Symptom relief |
| OAB | Solifenacin | Brand must be verified | Antimuscarinic therapy |
| Musculoskeletal Pain | Paracetamol | Napa | Analgesic |
| Local OA Pain | Diclofenac Gel | Voligel Max | Topical anti-inflammatory |
| Inflammatory Arthritis | Methotrexate | Methox | Conventional DMARD |
| Selected Established RA | Tofacitinib | Tofatin XR | Targeted synthetic DMARD |
| Neuropathic Pain | Mirogabalin | Merolin, Migalin | Neuropathic analgesic |
| GERD | Esomeprazole | Zo-MUPS | Acid suppression |
| Reflux Symptoms | Alginate combination | Gavirad | Reflux symptom relief |
| Dry Cough | Dextromethorphan | Brofex TS | Cough suppression |
Important: Table-āĻ āĻĨāĻžāĻāĻž āĻāĻŋāĻā§ brand āϏāϰāĻžāϏāϰāĻŋ MedEx-āĻ āϝāĻžāĻāĻžāĻ āĻāϰāĻž āĻšāϝāĻŧā§āĻā§; āϝā§āĻā§āϞā§āϰ āĻĒāĻžāĻļā§ brand verification āĻāϞā§āϞā§āĻ āĻāĻā§, āϏā§āĻāĻžāύ⧠generic-level therapeutic option āĻĻā§āĻāĻžāύ⧠āĻšāϝāĻŧā§āĻā§, āύāĻŋāϰā§āĻĻāĻŋāώā§āĻ Bangladesh brand āύāĻŋāĻļā§āĻāĻŋāϤ āĻāϰāĻž āĻšāϝāĻŧāύāĻŋāĨ¤
Confidence: 0.96 â Broad drug classes; individual patient suitability requires assessment.
Condition-specific prescribing principles
UTI: Antibiotic selection āĻšāĻŦā§ syndrome, renal function, organism susceptibility āĻ local resistance pattern āĻ āύā§āϝāĻžāϝāĻŧā§āĨ¤
OAB: Behavioral Therapy āĻĒā§āϰāĻĨāĻŽ āϧāĻžāĻĒā§āϰ āĻā§āϰā§āϤā§āĻŦāĻĒā§āϰā§āĻŖ āĻ āĻāĻļāĨ¤ Pharmacotherapy-āĻāϰ āĻā§āώā§āϤā§āϰ⧠hypertension, urinary retention āĻāĻŦāĻ cognitive risk āĻŦāĻŋāĻŦā§āĻā§āϝāĨ¤
RA: Methotrexate āĻāĻāĻāĻŋ āĻā§āϰā§āϤā§āĻŦāĻĒā§āϰā§āĻŖ conventional DMARD; āϤāĻŦā§ āĻāĻāĻŋ āϰā§āĻ āύāĻŋāĻļā§āĻāĻŋāϤ āĻšāĻāϝāĻŧāĻž, contraindication screening āĻāĻŦāĻ monitoring āĻāĻžāĻĄāĻŧāĻž āĻŦā§āϝāĻŦāĻšāĻžāϰ āĻāϰāĻž āϝāĻžāϝāĻŧ āύāĻžāĨ¤ JAK inhibitor āϏāĻŦ RA āϰā§āĻā§āϰ āĻĒā§āϰāĻĨāĻŽ āĻāĻŋāĻāĻŋā§āϏāĻž āύāϝāĻŧāĨ¤
Pain: ā§Žā§Ģ āĻŦāĻāϰ āĻŦāϝāĻŧāϏ⧠āĻĻā§āϰā§āĻāĻŽā§āϝāĻŧāĻžāĻĻāĻŋ systemic NSAID āĻŦā§āϝāĻŦāĻšāĻžāϰā§āϰ āĻĒāϰāĻŋāĻŦāϰā§āϤ⧠safer alternatives āĻāĻŦāĻ nonpharmacological treatment āĻŽā§āϞā§āϝāĻžāϝāĻŧāύ āĻā§āϰā§āϤā§āĻŦāĻĒā§āϰā§āĻŖāĨ¤
Confidence: 0.96
12. Important Drug Interactions and Geriatric Safety Analysis
āĻāĻ āĻĒā§āϰā§āϏāĻā§āϰāĻŋāĻĒāĻļāύā§āϰ āϏāĻŦāĻā§āϝāĻŧā§ āĻā§āϰā§āϤā§āĻŦāĻĒā§āϰā§āĻŖ clinical āϏāĻŽāϏā§āϝāĻžāĻā§āϞ⧠āύāĻŋāĻā§ āĻĻā§āĻāϝāĻŧāĻž āĻšāϞā§āĨ¤
| Drug Combination / Issue | Potential Risk | Clinical Priority |
|---|---|---|
| Brofex TS written dose | Possible excessive daily dose | đ´ Immediate verification |
| Tofacitinib + possible infection | Serious infection risk | đ´ High |
| Tofacitinib at age 85 | Infection, MACE, malignancy, thrombosis considerations | đ´ High |
| Sulindac 400 mg/day | GI bleeding and renal injury | đ´ High |
| Sulindac + topical Diclofenac | Additional NSAID exposure | đ Moderate |
| Mirogabalin + Flavoxate | Additive dizziness/sedation, falls | đ Moderate |
| Mirabegron + Flavoxate | Potential urinary retention risk | đ Moderate |
| Nitrofurantoin + impaired renal function | Reduced suitability/efficacy, toxicity | đ´ High |
| Gavirad + other oral medications | Possible reduced absorption | đ Moderate |
| Esomeprazole 40 mg twice daily | Indication for high-dose PPI unclear | đ Review |
Confidence: 0.94
Three major concerns requiring review
1. Brofex TS dose discrepancy: Written regimen appears to exceed the manufacturer’s listed maximum daily amount.
2. Tofacitinib: At age 85, the riskâbenefit balance must be reviewed carefully, especially with possible infection and no documented RA history.
3. Sulindac: Prescription reaches the MedEx maximum daily dose in an elderly patient whose renal function and GI risk are unknown.
Confidence: 0.99 â Importance of review.
13. Clinical Action Plan â āĻā§āĻāĻžāĻŦā§ āϰā§āĻā§āĻā§ āĻŽā§āϞā§āϝāĻžāϝāĻŧāύ āĻāϰāĻŦā§āύ
Step 1 â Immediate Medication Reconciliation
āϰā§āĻā§āϰ āϏāĻā§āĻā§ āĻŦā§āϝāĻŦāĻšā§āϤ āϏāĻŦ āĻāώā§āϧā§āϰ strip/bottle āύāĻŋāϝāĻŧā§ prescription āĻŽāĻŋāϞāĻŋāϝāĻŧā§ āĻĻā§āĻāϤ⧠āĻšāĻŦā§āĨ¤ āĻŦāĻŋāĻļā§āώāϤ Brofex TS, Merolin, Tofatin XR āĻāĻŦāĻ Sudac āϝāĻžāĻāĻžāĻ āĻāϰā§āύāĨ¤
Confidence: 0.99
Step 2 â Evaluate for Infection
Fever, Dysuria, Suprapubic Pain, Flank Pain, Hematuria, systemic illness āĻ āĻĨāĻŦāĻž new confusion āϰāϝāĻŧā§āĻā§ āĻāĻŋ āύāĻž āϝāĻžāĻāĻžāĻ āĻāϰā§āύāĨ¤
Sepsis, acute systemic deterioration āĻŦāĻž suspected pyelonephritis āĻĨāĻžāĻāϞ⧠āĻāϰā§āϰāĻŋ āĻāĻŋāĻāĻŋā§āϏāĻž āĻĒā§āϰāϝāĻŧā§āĻāύāĨ¤
Confidence: 0.98
Step 3 â Assess Renal Function
Serum Creatinine, eGFR, āĻĒā§āϰāϝāĻŧā§āĻāύ⧠CockcroftâGault Creatinine Clearance āĻāĻŦāĻ electrolyte status āĻĒāϰā§āĻā§āώāĻž āĻāϰā§āύāĨ¤
Confidence: 0.99
Step 4 â Assess Urinary Symptoms
Bladder Diary, Urgency, Frequency, Incontinence, nocturnal urine volume āĻ PVR āĻŽā§āϞā§āϝāĻžāϝāĻŧāύ āĻāϰā§āύāĨ¤
Confidence: 0.98
Step 5 â Evaluate Joint Pain
Joint swelling, Morning Stiffness, range of motion, neurological symptoms āĻāĻŦāĻ appropriate inflammatory markers āĻĒāϰā§āĻā§āώāĻž āĻāϰā§āύāĨ¤
Confidence: 0.96
Step 6 â Review High-Risk Drugs
Rheumatologist/Prescriber āĻĻāĻŋāϝāĻŧā§ Tofacitinib-āĻāϰ indication āĻāĻŦāĻ Geriatric Medicine/Clinical Pharmacy āĻĻāĻŋāϝāĻŧā§ Polypharmacy review āĻāϰāĻž āĻāĻāĻŋāϤāĨ¤
Confidence: 0.98
14. Specialist Referral â āĻā§āύ āĻĄāĻžāĻā§āϤāĻžāϰā§āϰ āĻāĻžāĻā§ āĻĒāĻžāĻ āĻžāĻŦā§āύ?
Primary Referral: Medicine Specialist / Geriatric Medicine
Reason: ā§Žā§Ģ āĻŦāĻāϰ āĻŦāϝāĻŧāϏ, āĻāĻāĻžāϧāĻŋāĻ āĻāĻĒāϏāϰā§āĻ, Polypharmacy āĻāĻŦāĻ significant drug-safety concernsāĨ¤
Priority: Prompt review, ideally within 24 hours for medication reconciliation; earlier if currently unwell or adverse effects are suspectedāĨ¤
Confidence: 0.97
Urologist
Persistent Nocturia, Urgency, urinary retention, hematuria āĻ āĻĨāĻŦāĻž abnormal PVR āĻĨāĻžāĻāϞā§āĨ¤
Confidence: 0.95
Rheumatologist
āĻāĻā§ āĻĨā§āĻā§ RA diagnosis āĻĨāĻžāĻāϞā§, inflammatory synovitis āĻĒāĻžāĻāϝāĻŧāĻž āĻā§āϞ⧠āĻ āĻĨāĻŦāĻž Tofacitinib treatment-āĻāϰ indication āϝāĻžāĻāĻžāĻ āĻāϰāϤā§āĨ¤
Confidence: 0.99
Nephrologist
Significant renal impairment, unexplained renal deterioration āĻ āĻĨāĻŦāĻž relevant abnormal renal findings āĻĨāĻžāĻāϞā§āĨ¤
Confidence: 0.96
15. Clinical Diagnosis Note & Illustrative Prescription Demo
A. Specific Provisional Dx Note
āĻāĻŋāĻāĻŋā§āϏāĻā§āϰ Clinical Record-āĻ, āϝāĻĨāĻžāϝāĻĨ āϝāĻžāĻāĻžāĻāϝāĻŧā§āϰ āĻĒāϰ, āύāĻŋāĻā§āϰ āĻŽāϤ⧠āĻāĻāĻāĻŋ provisional assessment note āĻŦā§āϝāĻŦāĻšāĻžāϰ āĻāϰāĻž āϝā§āϤ⧠āĻĒāĻžāϰā§āĨ¤
Provisional Dx:
1. Symptomatic Nocturia â Etiology Undetermined; R/O OAB, Symptomatic Lower UTI and Nocturnal Polyuria.
āĻŦāĻžāĻāϞāĻž: āϰāĻžāϤ⧠āĻŦāĻžāϰāĻŦāĻžāϰ āĻĒā§āϰāϏā§āϰāĻžāĻŦ āĻšāĻāϝāĻŧāĻž; āĻāĻžāϰāĻŖ āĻ āύāĻŋāϰā§āϧāĻžāϰāĻŋāϤāĨ¤ āĻ āϤāĻŋāϏāĻā§āϰāĻŋāϝāĻŧ āĻŽā§āϤā§āϰāĻĨāϞāĻŋ, āĻŽā§āϤā§āϰāύāĻžāϞā§āϰ āϏāĻāĻā§āϰāĻŽāĻŖ āĻ āϰāĻžāϤ⧠āĻ āϤāĻŋāϰāĻŋāĻā§āϤ āĻĒā§āϰāϏā§āϰāĻžāĻŦ āĻā§āĻĒāĻžāĻĻāύ āĻāĻā§ āĻāĻŋ āύāĻž āĻŽā§āϞā§āϝāĻžāϝāĻŧāύ āĻāϰāϤ⧠āĻšāĻŦā§āĨ¤
2. Bilateral Shoulder Pain with Low Back Pain â Etiology Undetermined; R/O Degenerative/Inflammatory Musculoskeletal Disease.
āĻŦāĻžāĻāϞāĻž: āĻāĻāϝāĻŧ āĻāĻžāĻāϧ āĻ āĻā§āĻŽāϰā§āϰ āĻŦā§āϝāĻĨāĻž; āĻā§āώāϝāĻŧāĻāύāĻŋāϤ āĻ āĻĨāĻŦāĻž āĻĒā§āϰāĻĻāĻžāĻšāĻāύāĻŋāϤ āϰā§āĻā§āϰ āϏāĻŽā§āĻāĻžāĻŦāύāĻž āĻŽā§āϞā§āϝāĻžāϝāĻŧāύ āĻāϰāϤ⧠āĻšāĻŦā§āĨ¤
3. Insomnia, Possibly Secondary to Nocturia/Pain.
āĻŦāĻžāĻāϞāĻž: āĻ āύāĻŋāĻĻā§āϰāĻž; āĻĒā§āϰāϏā§āϰāĻžāĻŦā§āϰ āϏāĻŽāϏā§āϝāĻž āĻ āĻĨāĻŦāĻž āĻŦā§āϝāĻĨāĻžāϰ āϏāĻā§āĻā§ āϏāĻŽā§āĻĒāϰā§āĻ āĻĨāĻžāĻāϤ⧠āĻĒāĻžāϰā§āĨ¤
4. Acute Upper Respiratory Symptoms â Possible Viral URTI.
āĻŦāĻžāĻāϞāĻž: āϏāĻžāϧāĻžāϰāĻŖ āϏāϰā§āĻĻāĻŋ-āĻāĻžāϤā§āϝāĻŧ āĻāĻĒāϏāϰā§āĻ; āϏāĻŽā§āĻāĻžāĻŦā§āϝ āĻāĻžāĻāϰāĻžāϏāĻāύāĻŋāϤ āĻāϰā§āϧā§āĻŦāĻļā§āĻŦāĻžāϏāύāĻžāϞā§āϰ āϏāĻāĻā§āϰāĻŽāĻŖāĨ¤
5. Medication Safety Review Required â High-Risk Polypharmacy.
āĻŦāĻžāĻāϞāĻž: āĻāĻāĻžāϧāĻŋāĻ āĻāĻā§āĻāĻā§āĻāĻāĻŋāϰ āĻāώā§āϧ āĻŦā§āϝāĻŦāĻšāĻžāϰā§āϰ āĻāĻžāϰāĻŖā§ āĻāώā§āϧā§āϰ āύāĻŋāϰāĻžāĻĒāϤā§āϤāĻž āĻĒā§āύāϰā§āĻŽā§āϞā§āϝāĻžāϝāĻŧāύ āĻĒā§āϰāϝāĻŧā§āĻāύāĨ¤
Confidence: 0.91 â Suitable problem-oriented provisional documentation.
B. Illustrative Clinical Review Prescription
Educational Example Only â Not a Valid Treatment Prescription
Patient: Mrs. Minoty Roy
Age: 85 years
Date: 16 October 2026
C/C: Nocturia, LBP, Bilateral Shoulder Pain, Insomnia, Common Cold.
O/E: BP 110/70 mmHg; Pulse 96/min; SpOâ 99%.
Provisional Dx: Symptomatic Nocturia, Etiology Undetermined; Musculoskeletal Pain; Possible URTI.
Investigations / Review:
- Review available Urine R/M/E, Creatinine/eGFR, RBS and Lower-Abdominal USG.
- Urine Culture if clinically suspected symptomatic UTI.
- CBC, ESR/CRP and Anti-CCP if inflammatory arthritis is suspected.
- PVR, bladder diary and focused musculoskeletal examination.
- Review current medication packs and doses before continuing the regimen.
- Verify the indication and safety monitoring for Tofacitinib.
Management: No new medicine prescribed in this educational example. Existing treatment requires clinician-led medication reconciliation and dose verification.
Referral: Medicine/Geriatrics; Urology and Rheumatology as indicated.
Follow-up: Prompt medication review and reassessment after available laboratory results.
Confidence: 0.97 â Safety-focused example; not an authorization to prescribe.
16. Overview / Summary & Final Clinical Assessment
Final Working Clinical Assessment
This 85-year-old woman presents with nocturia, bilateral shoulder pain, low back pain, insomnia and common cold symptoms. The available prescription suggests treatment directed toward urinary symptoms, possible UTI, musculoskeletal pain and possible inflammatory arthritis. However, no definitive diagnosis is documented, and the requested investigations have not been supplied.
āĻŦāĻžāĻāϞāĻžāϝāĻŧ Clinical Conclusion
ā§Žā§Ģ āĻŦāĻāϰ āĻŦāϝāĻŧāϏ⧠āĻāĻ āϰā§āĻā§āϰ āĻĒā§āϰāϧāĻžāύ āϏāĻŽāϏā§āϝāĻž āϰāĻžāϤ⧠āĻŦāĻžāϰāĻŦāĻžāϰ āĻĒā§āϰāϏā§āϰāĻžāĻŦ āĻšāĻāϝāĻŧāĻž, āĻāĻāϝāĻŧ āĻāĻžāĻāϧ āĻ āĻā§āĻŽāϰā§āϰ āĻŦā§āϝāĻĨāĻž, āĻ āύāĻŋāĻĻā§āϰāĻž āĻāĻŦāĻ āϏāϰā§āĻĻāĻŋāĨ¤
āĻĒā§āϰā§āϏāĻā§āϰāĻŋāĻĒāĻļāύā§āϰ āĻāώā§āϧ āĻĻā§āĻā§ āĻŦā§āĻāĻž āϝāĻžāϝāĻŧ āĻĄāĻžāĻā§āϤāĻžāϰ āĻĒā§āϰāϏā§āϰāĻžāĻŦā§āϰ āϏāĻŽāϏā§āϝāĻž, āϏāĻŽā§āĻāĻžāĻŦā§āϝ āϏāĻāĻā§āϰāĻŽāĻŖ āĻāĻŦāĻ āĻĒā§āϰāĻĻāĻžāĻšāĻāύāĻŋāϤ āĻŦā§āϝāĻĨāĻžāϰ āĻāĻŋāĻāĻŋā§āϏāĻž āĻāϰā§āĻā§āύāĨ¤
āϤāĻŦā§ Overactive Bladder, UTI āĻŦāĻž Rheumatoid ArthritisâāĻā§āύā§āĻāĻŋāĻ āĻŦāϰā§āϤāĻŽāĻžāύ⧠āύāĻŋāĻļā§āĻāĻŋāϤ āĻŦāϞāĻž āϝāĻžāĻŦā§ āύāĻžāĨ¤
āĻĒā§āϰāĻĨāĻŽ āĻāĻžāĻ āĻšāϞ⧠āϰā§āĻā§āϰ āĻĒā§āϰāĻā§āϤ āϏāĻŽāϏā§āϝāĻž āύāĻŋāϰā§āĻŖāϝāĻŧ āĻāϰāĻž, āĻāĻŋāĻĄāύāĻŋāϰ āĻāĻžāϰā§āϝāĻāĻžāϰāĻŋāϤāĻž āϝāĻžāĻāĻžāĻ āĻāϰāĻž āĻāĻŦāĻ āĻāώā§āϧāĻā§āϞā§āϰ āύāĻŋāϰāĻžāĻĒāϤā§āϤāĻž āĻĒā§āύāϰā§āĻŽā§āϞā§āϝāĻžāϝāĻŧāύ āĻāϰāĻžāĨ¤
Final Confidence Assessment
| Clinical Conclusion | Confidence |
|---|---|
| Correct identification of the main documented complaints | 0.99 |
| No explicit Doctor’s Dx documented | 0.99 |
| Patient requires medication-safety review | 0.99 |
| Brofex TS written-dose discrepancy | 0.96 |
| Nocturia is a genuine documented problem | 0.99 |
| Underlying OAB is possible | 0.56 |
| Symptomatic UTI is possible | 0.43 |
| Rheumatoid Arthritis is confirmed | 0.25 â Not supported |
| Definitive overall diagnosis can be established from this image alone | 0.15 â Not supported |
Final Assessment Confidence: 0.89 for the structured provisional assessment, but substantially lower for any individual etiological diagnosis.
17. References â Textbooks, Guidelines & Peer-Reviewed Evidence
A. Standard Medical Textbooks
1. Harrison’s Principles of Internal Medicine. 22nd Edition. McGraw Hill, 2025. Relevant sections: Urinary Tract Infection, Rheumatoid Arthritis, Musculoskeletal Disorders and Geriatric Medicine.
2. Davidson’s Principles and Practice of Medicine. Elsevier. Relevant sections: Renal/Urinary Disorders and Rheumatic Diseases.
3. Goodman & Gilman’s The Pharmacological Basis of Therapeutics. 14th Edition. McGraw Hill, 2022. Relevant sections: Anti-infectives, NSAIDs and Immunomodulatory Pharmacology.
4. Katzung’s Basic & Clinical Pharmacology. 16th Edition. McGraw Hill. Relevant sections: Antimicrobial Agents, Anti-inflammatory Drugs and Immunopharmacology.
5. Robbins & Cotran Pathologic Basis of Disease. Relevant sections: Urinary System and Immune-Mediated Inflammatory Diseases.
Note: āύāĻŋāϰā§āĻĻāĻŋāώā§āĻ chapter/page numbers āĻāĻāĻžāύ⧠primary textbook āĻĨā§āĻā§ āϏāϰāĻžāϏāϰāĻŋ āϝāĻžāĻāĻžāĻ āĻāϰāĻž āĻšāϝāĻŧāύāĻŋ; āϤāĻžāĻ āĻ āύā§āĻŽāĻžāύ āĻāϰ⧠page number āĻĻā§āĻāϝāĻŧāĻž āĻšāϝāĻŧāύāĻŋāĨ¤
B. International Clinical Guidelines
6. AUA/SUFU Guideline, 2024: Diagnosis and Treatment of Idiopathic Overactive Bladder.
DOI: 10.1097/JU.0000000000003985.
7. IDSA Clinical Practice Guideline, 2019: Management of Asymptomatic Bacteriuria.
DOI: 10.1093/cid/ciz021.
8. NICE NG109: Urinary Tract Infection (Lower): Antimicrobial Prescribing.
NICE Guideline NG109
9. EULAR Recommendations, 2025 Update (Published 2026): Management of Rheumatoid Arthritis with DMARDs.
DOI: 10.1016/j.ard.2026.01.023.
10. AGS Beers Criteria, 2023: Potentially Inappropriate Medication Use in Older Adults.
DOI: 10.1111/jgs.18372.
11. FDA Drug Safety Communication, 2021: Safety Warnings for JAK Inhibitors Including Tofacitinib.
FDA Safety Communication
C. Peer-Reviewed Research Articles
12. Ytterberg SR, et al. Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis. New England Journal of Medicine. 2022;386:316â326.
DOI: 10.1056/NEJMoa2109927.
13. Aletaha D, et al. 2010 Rheumatoid Arthritis Classification Criteria. Arthritis & Rheumatism. 2010;62:2569â2581.
DOI: 10.1002/art.27584.
14. Dasgupta B, et al. 2012 Provisional Classification Criteria for Polymyalgia Rheumatica. Arthritis & Rheumatism. 2012.
DOI: 10.1002/art.34356.
D. Bangladesh Drug Reference
15. MedEx Bangladesh: Brand-specific and generic drug monographs for all ten prescription medicines.
āĻĒā§āϰāϤāĻŋāĻāĻŋ āĻāώā§āϧā§āϰ MedEx link āϏāĻāĻļā§āϞāĻŋāώā§āĻ Drug Analysis āĻ āĻāĻļā§ āĻĻā§āĻāϝāĻŧāĻž āĻšāϝāĻŧā§āĻā§āĨ¤
âī¸ Author Information
Author: Md.Rafiqul Islam Lipu
Publication Series: LIPU MED â Clinical Prescription Review
Department: Urology
Proposed Total Case: 1377
Department Code: 23
Proposed Department Case Number: 25
Date: Friday, 16 October 2026
Time: 5:43 PM (Bangladesh Standard Time; time verified during this review)
Article Status: Clinical draft â requiring medication-name confirmation, investigation results and clinician validation before patient-specific treatment recommendations or publication as a final diagnosis.
Final Clinical Note: āĻāĻ āĻĒā§āϰā§āϏāĻā§āϰāĻŋāĻĒāĻļāύā§āϰ āϏāĻŦāĻā§āϝāĻŧā§ āĻā§āϰā§āϤā§āĻŦāĻĒā§āϰā§āĻŖ āĻŦāĻŋāώāϝāĻŧ āĻļā§āϧ⧠āϰā§āĻ āύāĻŋāϰā§āĻŖāϝāĻŧ āύāϝāĻŧ; ā§Žā§Ģ āĻŦāĻāϰ āĻŦāϝāĻŧāϏ⧠āϰā§āĻā§āϰ āĻā§āώā§āϤā§āϰ⧠Brofex TS-āĻāϰ āϏāĻŽā§āĻāĻžāĻŦā§āϝ āĻ āϤāĻŋāϰāĻŋāĻā§āϤ āĻĄā§āĻ, Tofacitinib-āĻāϰ āĻāĻā§āĻāĻā§āĻāĻāĻŋāϰ āĻŦā§āϝāĻŦāĻšāĻžāϰ āĻāĻŦāĻ Sulindac-āĻāϰ renal/GI safety āĻĻā§āϰā§āϤ āϝāĻžāĻāĻžāĻ āĻāϰāĻžāĨ¤ āĻāĻā§āϞ⧠āĻŽā§āϞā§āϝāĻžāϝāĻŧāύ āύāĻž āĻāϰ⧠āĻā§āύ⧠āύāĻŋāϰā§āĻĻāĻŋāώā§āĻ āϰā§āĻāĻā§ āύāĻŋāĻļā§āĻāĻŋāϤ āĻŦāĻž āĻāĻŋāĻāĻŋā§āϏāĻžāĻā§ āϏāĻŽā§āĻĒā§āϰā§āĻŖ āύāĻŋāϰāĻžāĻĒāĻĻ āĻŦāϞāĻž āϝāĻžāĻŦā§ āύāĻžāĨ¤